

Hepatocellular carcinoma

Nature Reviews Disease Primers

7, 6

DOI: [10.1038/s41572-020-00240-3](https://doi.org/10.1038/s41572-020-00240-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Systemic characterization of the SLC family genes reveals SLC26A6 as a novel oncogene in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2882-2894.	0.4	6
2	Therapeutic effects of boronate ester cross-linked injectable hydrogels for the treatment of hepatocellular carcinoma. <i>Biomaterials Science</i> , 2021, 9, 7275-7286.	2.6	14
3	ASO Author Reflections: Treatment for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus—Anatomic Resection Should Be Recommended. <i>Annals of Surgical Oncology</i> , 2021, 28, 7696-7697.	0.7	0
4	Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. <i>Cancers</i> , 2021, 13, 1422.	1.7	31
5	FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 1360.	1.7	24
6	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
7	HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	6
8	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. <i>Frontiers in Immunology</i> , 2021, 12, 643310.	2.2	27
9	Sulfatase 2-Induced Cancer-Associated Fibroblasts Promote Hepatocellular Carcinoma Progression via Inhibition of Apoptosis and Induction of Epithelial-to-Mesenchymal Transition. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 631931.	1.8	14
10	Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes?. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	1
11	Obesity and Liver Cancer in Japan: A Comprehensive Review. <i>Anticancer Research</i> , 2021, 41, 2227-2237.	0.5	5
12	LncRNA ILF3-AS1 promotes cell migration, invasion and EMT process in hepatocellular carcinoma via the miR-628-5p/MEIS2 axis to activate the Notch pathway. <i>Digestive and Liver Disease</i> , 2022, 54, 125-135.	0.4	8
13	Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. <i>Cancers</i> , 2021, 13, 2708.	1.7	19
14	Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 11201.	1.6	4
15	A TGF β 2 Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGF β 2-independent Manner. <i>Anticancer Research</i> , 2021, 41, 2431-2440.	0.5	1
16	Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7624-7633.	0.7	4
17	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	1.8	182
18	LINC00261: a burgeoning long noncoding RNA related to cancer. <i>Cancer Cell International</i> , 2021, 21, 274.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis. <i>Carcinogenesis</i> , 2021, 42, 1026-1036.	1.3	4
20	The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. <i>Cancers</i> , 2021, 13, 2651.	1.7	18
21	Can BOLD fMRI Demonstrate Early Response to Chemoembolization in HCCs?. <i>Academic Radiology</i> , 2021, 28 Suppl 1, S20-S21.	1.3	1
22	Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. <i>Cancers</i> , 2021, 13, 2700.	1.7	6
23	Mitochondrial Dynamics and Liver Cancer. <i>Cancers</i> , 2021, 13, 2571.	1.7	17
24	DNA Framework-based Topological Aptamer for Differentiating Subtypes of Hepatocellular Carcinoma Cells. <i>Chemical Research in Chinese Universities</i> , 2021, 37, 919-924.	1.3	4
25	Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. <i>Journal of Ethnopharmacology</i> , 2021, 274, 114073.	2.0	23
26	Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. <i>Cancers</i> , 2021, 13, 2899.	1.7	58
27	Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases. <i>Liver Research</i> , 2021, , .	0.5	2
29	Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1141-1151.	0.6	2
30	Ariadne's Thread in the Network of Hepatocellular Carcinoma Immunobiology. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	0
31	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. <i>Cancers</i> , 2021, 13, 2786.	1.7	44
32	Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 713-739.	1.8	10
33	The TGF- β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021, 13, 3248.	1.7	37
34	Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Cancers</i> , 2021, 13, 2984.	1.7	22
35	Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6401.	1.8	7
36	The Role of Oxidative Stress in NAFLD to "NASH" to HCC Transition Focus on NADPH Oxidases. <i>Biomedicines</i> , 2021, 9, 687.	1.4	46
37	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 371-378.	1.9	65

#	ARTICLE	IF	CITATIONS
38	Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3
39	Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 837-850.	1.8	2
40	Hepatocellular Carcinoma "Origins and Outcomes. <i>New England Journal of Medicine</i> , 2021, 385, 280-282.	13.9	60
41	Effects of Buffer Concentration on the Sensitivity of Silicon Nanobelt Field-Effect Transistor Sensors. <i>Sensors</i> , 2021, 21, 4904.	2.1	5
42	RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2022, 22, 229-243.	1.9	6
43	BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. <i>Cell Death and Disease</i> , 2021, 12, 736.	2.7	10
44	Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3771.	1.7	7
45	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2022, 54, 154-163.	0.4	15
46	The immunological and metabolic landscape in primary and metastatic liver cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 541-557.	12.8	212
47	SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/ β -catenin/MYC/HMGCS2 axis. <i>British Journal of Cancer</i> , 2021, 125, 865-876.	2.9	33
48	Prognostic Role and Potential Mechanisms of N6-methyladenosine-related Long Noncoding RNAs in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 308-320.	0.7	4
49	Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients. <i>Scientific Reports</i> , 2021, 11, 15184.	1.6	2
50	The Cytosolic DNA-Sensing cGAS-STING Pathway in Liver Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 717610.	1.8	9
51	On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3758.	1.7	8
52	Association of Polymorphisms in the Glutathione S-Transferase Theta-1 Gene with Cirrhosis and Hepatocellular Carcinoma in Brazilian Patients with Chronic Hepatitis C. <i>Vaccines</i> , 2021, 9, 831.	2.1	3
53	Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101781.	0.7	13
54	Evolving therapeutic strategies for advanced hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-12.	0.9	2
55	Hepatic IFNL4 Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7803.	1.8	1

#	ARTICLE	IF	CITATIONS
56	Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. <i>World Chinese Journal of Digestology</i> , 2021, 29, 677-683.	0.0	0
57	Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-8.	2.0	4
58	Second Primary Malignancies in Patients With Hepatocellular Carcinoma: A Population-Based Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 713637.	1.3	6
59	Synthesis, SAR study, and bioactivity evaluation of a series of Quinoline-Indole-Schiff base derivatives: Compound 10E as a new Nur77 exporter and autophagic death inducer. <i>Bioorganic Chemistry</i> , 2021, 113, 105008.	2.0	7
61	Ginsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 10121-10137.	2.4	20
62	Hsp90 Inhibitor STA9090 Sensitizes Hepatocellular Carcinoma to Hyperthermia-Induced DNA Damage by Suppressing DNA-PKcs Protein Stability and mRNA Transcription. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1880-1892.	1.9	7
63	SALL4 and microRNA: The Role of Let-7. <i>Genes</i> , 2021, 12, 1301.	1.0	7
64	Telocytes promote hepatocellular carcinoma by activating the ERK signaling pathway and miR-942-3p/MMP9 axis. <i>Cell Death Discovery</i> , 2021, 7, 209.	2.0	10
65	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1159-1167.	1.4	6
66	RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 666001.	1.3	6
67	Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1153-1165.	1.4	13
68	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 147-158.	0.7	21
69	SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/ β -Catenin Signaling Pathway in Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 701454.	1.6	5
70	Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1838-1850.	0.6	4
71	Intelligent Algorithm-Based Computed Tomography Image Features in Diagnosis of the Effect of Radiofrequency Ablation in Liver Cancer. <i>Scientific Programming</i> , 2021, 2021, 1-9.	0.5	1
72	Effect of Overpressure on Acoustic Emissions and Treated Tissue Histology in ex Vivo Bulk Ultrasound Ablation. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2360-2376.	0.7	1
73	Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 997-1021.	1.8	11
74	Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 134.	6.9	70

#	ARTICLE	IF	CITATIONS
75	Tribbles pseudokinase 3 (TRIB3) contributes to the progression of hepatocellular carcinoma by activating the mitogen-activated protein kinase pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 1253-1253.	0.7	6
76	Prognostic Role and Potential Mechanisms of the Ferroptosis-Related Metabolic Gene Signature in Hepatocellular Carcinoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 927-945.	0.4	7
77	DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features. <i>Frontiers in Immunology</i> , 2021, 12, 715460.	2.2	14
78	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 927-939.	1.1	9
79	Systematic Analysis of Cytostatic TGF-Beta Response in Mesenchymal-Like Hepatocellular Carcinoma Cell Lines. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 1320-1335.	0.6	3
80	GATNNCCA: A Method Based on Graph Attention Network and Multi-Layer Neural Network for Predicting circRNA-Disease Associations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8505.	1.8	7
81	Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9380.	1.8	1
82	The promise of radiotherapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 837-838.	1.8	5
83	The expression and prognostic value of REXO4 in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1704-1717.	0.6	4
84	Prognostic risk scores for liver transplantation: game changers or statistical artworks?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 553-557.	0.7	1
85	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9044.	1.8	7
86	Proliferative versus Nonproliferative Hepatocellular Carcinoma: Clinical and Imaging Implications. <i>Radiology</i> , 2021, 300, 583-585.	3.6	1
87	CK19 Predicts Recurrence and Prognosis of HBV Positive HCC. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 341-351.	0.9	9
89	Uncovering the Association Between m5C Regulator-Mediated Methylation Modification Patterns and Tumour Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 727935.	1.8	15
90	Medical therapy of HCC. <i>Journal of Hepatology</i> , 2022, 76, 208-210.	1.8	11
91	Identification of a Prognostic Model Based on 2-Gene Signature and Analysis of Corresponding Tumor Microenvironment in Alcohol-Related Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 719355.	1.3	1
93	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1132-1143.	0.8	2
94	Liver cirrhosis. <i>Lancet, The</i> , 2021, 398, 1359-1376.	6.3	515

#	ARTICLE	IF	CITATIONS
95	Gly-tRF enhances LCSC-like properties and promotes HCC cells migration by targeting NDFIP2. <i>Cancer Cell International</i> , 2021, 21, 502.	1.8	18
96	An Overview of the Genomic Characterization of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1077-1088.	1.8	8
97	Integrated Analysis and Finding Reveal Anti-“Liver Cancer Targets and Mechanisms of Pachyman (Poria) Tj ETQq0.0.0 rgBT /Overlock 1	1.6	15
98	Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 709278.	1.3	11
99	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). <i>Gastroenterology</i> , 2021, 161, 879-898.	0.6	123
100	Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 736677.	1.8	18
101	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. <i>Seminars in Liver Disease</i> , 2022, 42, 087-103.	1.8	10
102	Minimally Invasive versus Open Liver Resection for Stage I/II Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4800.	1.7	7
103	Type I IFNs repolarized a CD169+ macrophage population with anti-tumor potentials in hepatocellular carcinoma. <i>Molecular Therapy</i> , 2022, 30, 632-643.	3.7	13
104	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2022, 76, 446-457.	1.8	121
105	Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. <i>World Journal of Hepatology</i> , 2021, 13, 1107-1121.	0.8	4
107	NIR-Responsive Hydrogel as an Angiogenesis Inhibition Agent for Tumor Microenvironment Reprogramming. <i>Small</i> , 2021, 17, e2103003.	5.2	24
108	Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report. <i>Journal of Liver Cancer</i> , 2021, 21, 169-176.	0.3	1
109	Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1109-1120.	0.8	4
110	IGF2BP1 promotes the liver cancer stem cell phenotype by regulating MGAT5 mRNA stability via m6A RNA methylation. <i>Stem Cells and Development</i> , 2021, 30, 1115-1125.	1.1	15
111	Effects of surgery, chemotherapy, and radiation on hepatocellular carcinoma patients: A SEER-based study. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102782.	0.5	1
112	Immunomodulatory Effects of Lenvatinib Plus Anti-“Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 2652-2669.	3.6	95
113	Pyroglutamate Aminopeptidase I Promotes Hepatocellular Carcinoma via IL-6/STAT3 Activation as Revealed by a Specific Biosensor. <i>Analytical Chemistry</i> , 2021, 93, 13311-13318.	3.2	9

#	ARTICLE	IF	CITATIONS
114	The Prognostic Model Based on Tumor Cell Evolution Trajectory Reveals a Different Risk Group of Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 737723.	1.8	3
115	Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma. <i>Bioorganic Chemistry</i> , 2021, 114, 105154.	2.0	20
116	Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 280.	3.5	10
117	Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1243-1255.	2.1	7
118	Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. <i>Biomedicines</i> , 2021, 9, 1158.	1.4	3
119	Knockout of Hepatocyte Growth Factor by CRISPR/Cas9 System Induces Apoptosis in Hepatocellular Carcinoma Cells. <i>Journal of Personalized Medicine</i> , 2021, 11, 983.	1.1	7
120	Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 737-740.	0.7	7
121	Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111960.	2.5	4
122	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 865-878.	1.8	111
123	Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. <i>Cancer Letters</i> , 2021, 520, 243-254.	3.2	8
124	Genetic polymorphisms in DNA repair genes and hepatocellular carcinoma risk. <i>DNA Repair</i> , 2021, 107, 103196.	1.3	3
125	Discovery of penipanoicid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113671.	2.6	10
126	A sandwich-type electrochemical immunosensor using rGO-TEPA-Thi-Au as sensitive platform and CMK-3@AuPtNPs as signal probe for AFP detection. <i>Microchemical Journal</i> , 2021, 170, 106641.	2.3	24
127	Mitoquinol mesylate alleviates oxidative damage in cirrhotic and advanced hepatocellular carcinogenic rats through mitochondrial protection and antioxidative effects. <i>Advances in Redox Research</i> , 2021, 3, 100014.	0.9	2
128	Viral integration detection strategies and a technical update on Virus-Clip. <i>Biocell</i> , 2021, 45, 1495-1500.	0.4	2
129	Development of a Deep Learning Model to Assist with Diagnosis of Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
130	Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 369-383.	1.0	14
131	Electrochemical aptasensors for the detection of hepatocellular carcinoma-related biomarkers. <i>New Journal of Chemistry</i> , 2021, 45, 15158-15169.	1.4	2

#	ARTICLE	IF	CITATIONS
132	The Clinical Significance of RMI2 in Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110454.	0.8	1
133	Diosmetin inhibits cell growth and proliferation by regulating the cell cycle and lipid metabolism pathway in hepatocellular carcinoma. <i>Food and Function</i> , 2021, 12, 12036-12046.	2.1	15
134	Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern. <i>Abdominal Radiology</i> , 2022, 47, 431-442.	1.0	2
135	Targeting CDC7 potentiates ATR-Chk1 signaling inhibition through induction of DNA replication stress in liver cancer. <i>Genome Medicine</i> , 2021, 13, 166.	3.6	19
136	First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. <i>Cancer Medicine</i> , 2021, 10, 8530-8541.	1.3	12
137	Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 333-350.	4.5	22
138	Management of Hepatitis B in Persons Who Inject Drugs (PWID). <i>Current Hepatology Reports</i> , 2021, 20, 158.	0.4	1
139	Circular RNA circ_0073181 contributes to tumorigenesis by regulating protein tyrosine phosphatase receptor type E via miR-548p in hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
140	The TRIM proteins in cancer: from expression to emerging regulatory mechanisms. <i>Clinical and Translational Oncology</i> , 2022, 24, 460-470.	1.2	12
141	Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. <i>Digestive Diseases</i> , 2022, 40, 565-580.	0.8	4
142	Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. <i>Cancers</i> , 2021, 13, 5250.	1.7	8
143	Outcomes of robotic-assisted liver surgery versus laparoscopic liver surgery for treatment of stage I hepatocellular carcinoma. <i>Cancer</i> , 2022, 128, 762-769.	2.0	11
144	Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. <i>Pathogens</i> , 2021, 10, 1366.	1.2	10
145	Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. <i>Cancers</i> , 2021, 13, 5045.	1.7	8
146	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 1275-1283.	0.7	12
147	Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 695635.	2.0	4
148	Combination therapy for HCC: from CRISPR screening to the design of clinical therapies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 359.	7.1	3
149	Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes. <i>Cancers</i> , 2021, 13, 5127.	1.7	15

#	ARTICLE	IF	CITATIONS
150	Initial Incomplete Thermal Ablation Is Associated With a High Risk of Tumor Progression in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 760173.	1.3	1
151	Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2–3 cm: Comparison of Resection and Ablation. <i>Frontiers in Oncology</i> , 2021, 11, 757149.	1.3	0
152	Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. <i>Pharmaceutics</i> , 2021, 13, 1631.	2.0	8
153	Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5180.	1.7	9
154	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 737497.	1.3	22
155	DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4981.	1.7	30
156	The Incidence of Bacteremia and Risk Factors of Post-Radiofrequency Ablation Fever for Patients with Hepato-Cellular Carcinoma. <i>Cancers</i> , 2021, 13, 5303.	1.7	2
157	Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGF β 2R Regulating TGF- β 2/Smad Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-21.	1.9	20
158	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. <i>Biomedicines</i> , 2021, 9, 1524.	1.4	10
159	CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1851-1867.	0.9	46
160	Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. <i>Advanced Science</i> , 2021, 8, e2102051.	5.6	35
161	Hepatocyte Polyploidy: Driver or Gatekeeper of Chronic Liver Diseases. <i>Cancers</i> , 2021, 13, 5151.	1.7	11
162	Wnt Signaling Pathway Is among the Drivers of Liver Metastasis. <i>Livers</i> , 2021, 1, 180-200.	0.8	2
164	Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2021, 13, 5349.	1.7	9
165	The Gut–Liver Axis in Chronic Liver Disease: A Macrophage Perspective. <i>Cells</i> , 2021, 10, 2959.	1.8	18
166	Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11770.	1.8	7
167	Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2021, 13, 5430.	1.7	13
168	Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. <i>Cancers</i> , 2021, 13, 5448.	1.7	5

#	ARTICLE	IF	CITATIONS
169	Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 8253-8271.	1.3	9
170	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. <i>Cancers</i> , 2021, 13, 5475.	1.7	10
171	Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?. <i>Frontiers in Immunology</i> , 2021, 12, 731527.	2.2	10
172	Identification of Immune-Related Genes for Establishment of Prognostic Index in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760079.	1.8	0
173	Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1311-1322.	1.8	7
174	Ferroptosis-mediated Crosstalk in the Tumor Microenvironment Implicated in Cancer Progression and Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 739392.	1.8	17
175	Identification and Validation of Pyroptosis-Related Gene Signature to Predict Prognosis and Reveal Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 748039.	1.8	51
176	High-Level Procalcitonin in Patient with Mixed Fibrolamellar Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	0.6	1
177	Clinical Value of Machine Learning-Based Ultrasomics in Preoperative Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 749137.	1.3	19
178	Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities. <i>Cancers</i> , 2021, 13, 5524.	1.7	15
179	The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. <i>Frontiers in Pharmacology</i> , 2021, 12, 771459.	1.6	16
180	Circ_0046600 promotes hepatocellular carcinoma progression via up-regulating SERBP1 through sequestering miR-1258. <i>Pathology Research and Practice</i> , 2021, 228, 153681.	1.0	4
181	Decoding therapy resistance in liver tumours: a giant leap. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, , .	8.2	0
182	Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5586.	1.7	13
183	In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling. <i>Cancers</i> , 2021, 13, 5583.	1.7	18
184	Two Novel Precursors of the HIV-1 Protease Inhibitor Darunavir Target the UPR/Proteasome System in Human Hepatocellular Carcinoma Cell Line HepG2. <i>Cells</i> , 2021, 10, 3052.	1.8	3
185	Hepatitis B Virus Promotes Hepatocellular Carcinoma Progression Synergistically With Hepatic Stellate Cells via Facilitating the Expression and Secretion of ENPP2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 745990.	1.6	3
186	Liver diseases fibrosis and cirrhosis. , 2022, , 107-153.		0

#	ARTICLE	IF	CITATIONS
187	Nucleoporin 93 mediates β -catenin nuclear import to promote hepatocellular carcinoma progression and metastasis. <i>Cancer Letters</i> , 2022, 526, 236-247.	3.2	13
188	The Construction of a Prognostic Model Based on a Peptidyl Prolyl Cis-Trans Isomerase Gene Signature in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 730141.	1.1	0
189	The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792667.	1.6	11
190	Analysis of Multi-Layer RNA Modification Patterns for the Characterization of Tumor Immune Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 761391.	1.8	1
191	Artificial Intelligent Multi-Modal Point-of-Care System for Predicting Response of Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 761548.	2.0	1
192	The Efficacy of Radiotherapy in the Treatment of Hepatocellular Carcinoma with Distant Organ Metastasis. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	0.6	5
193	Lymphoepithelioma-like Hepatocellular Carcinoma: a Case Report and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 275-281.	0.6	2
194	Changes in therapeutic options for hepatocellular carcinoma in Asia. <i>Liver International</i> , 2022, 42, 2055-2066.	1.9	14
195	Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. <i>Frontiers in Genetics</i> , 2021, 12, 717319.	1.1	10
196	A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation. <i>Cancer Nanotechnology</i> , 2021, 12, .	1.9	1
197	The prognostic value of TPM1 ⁴ in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, , .	1.3	11
198	Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	1
199	Design, synthesis and anti-hepatocellular carcinoma activity of 3-arylisquinoline alkaloids. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 113985.	2.6	4
200	Identification of a TGF- β 2/SMAD/Inc-UTGF positive feedback loop and its role in hepatoma metastasis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 395.	7.1	18
201	Serpinc1 Acts as a Tumor Suppressor in Hepatocellular Carcinoma Through Inducing Apoptosis and Blocking Macrophage Polarization in an Ubiquitin-Proteasome Manner. <i>Frontiers in Oncology</i> , 2021, 11, 738607.	1.3	6
202	Biejiajian Pill Promotes the Infiltration of CD8+ T Cells in Hepatocellular Carcinoma by Regulating the Expression of CCL5. <i>Frontiers in Pharmacology</i> , 2021, 12, 771046.	1.6	8
203	GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 397.	7.1	58
204	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43

#	ARTICLE	IF	CITATIONS
205	Autophagy-Induced HDAC6 Activity During Hypoxia Regulates Mitochondrial Energy Metabolism Through the β -Catenin/COUP-TFII Axis in Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 742460.	1.3	8
206	The Use of Machine Learning to Create a Risk Score to Predict Survival in Patients with Hepatocellular Carcinoma: A TCGA Cohort Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-8.	0.8	6
207	Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for <i>In Vivo</i> Imaging. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 54656-54664.	4.0	11
208	Biointerfacing Antagonizing T α Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy. <i>Small</i> , 2021, 17, e2105237.	5.2	2
209	On Efficacy of Microwave Ablation in the Thermal Treatment of an Early-Stage Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5784.	1.7	17
210	Establishment and Validation of an MTORC1 Signaling-Related Gene Signature to Predict Overall Survival in Patients with Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-15.	0.9	2
211	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
212	The Protein Kinase Activity of NME7 Activates Wnt/ β -Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 60-74.	0.4	15
213	Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101835.	0.7	5
214	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 364.	3.5	15
215	CT perfusion for response evaluation after interventional ablation of hepatocellular carcinoma: a prospective study. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2021, 52, .	0.3	2
216	AC093797.1 as a Potential Biomarker to Indicate the Prognosis of Hepatocellular Carcinoma and Inhibits Cell Proliferation, Invasion, and Migration by Reprogramming Cell Metabolism and Extracellular Matrix Dynamics. <i>Frontiers in Genetics</i> , 2021, 12, 778742.	1.1	0
217	Ventilagolin Suppresses Migration, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Downregulating Pim-1. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4885-4899.	2.0	5
218	Development of a Deep Learning Model to Assist With Diagnosis of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 762733.	1.3	6
219	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13051.	1.8	14
220	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. <i>ESMO Open</i> , 2021, 6, 100330.	2.0	25
221	Epidemiology and Outcomes of Hospitalizations Due to Hepatocellular Carcinoma. <i>Cureus</i> , 2021, 13, e20089.	0.2	1
222	Liver segmentation from computed tomography images using cascade deep learning. <i>Computers in Biology and Medicine</i> , 2022, 140, 105095.	3.9	24

#	ARTICLE	IF	CITATIONS
223	The microbiome, gastrointestinal cancer, and immunotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 263-272.	1.4	9
224	Comprehensive Molecular Analyses of a Macrophages-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and LASSO Algorithm. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
225	Single cell analysis informing therapy response in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	0.7	0
226	Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 78-93.	0.7	24
227	Identification of Macrotrabecular-Massive Hepatocellular Carcinoma and Prediction of Response to Transarterial Chemoembolization Plus Antiangiogenic Therapy Using Ct Radiomics. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
228	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232.	1.7	6
229	The hepatocellular carcinoma's risk factors among in-hospital patients at the university-teaching hospital Yalgado OuÃ©draogo in Ouagadougou, Burkina Faso: A case-control study. <i>Clinical Epidemiology and Global Health</i> , 2022, 13, 100947.	0.9	0
230	Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2. <i>Theranostics</i> , 2022, 12, 1097-1116.	4.6	14
231	Signature Construction and Molecular Subtype Identification Based on Pyroptosis-Related Genes for Better Prediction of Prognosis in Hepatocellular Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-20.	1.9	8
232	A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases. <i>Journal of Liver Cancer</i> , 0, , .	0.3	0
233	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology, The</i> , 2022, 23, 161-171.	5.1	36
234	Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	2
235	SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. <i>Cancer Letters</i> , 2022, 528, 16-30.	3.2	30
236	Minimally invasive liver surgery: the CharitÃ© experience. <i>Turkish Journal of Surgery</i> , 2021, 37, 199-206.	0.1	4
237	ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth. <i>Cancer Research</i> , 2022, 82, 900-915.	0.4	28
238	Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. , 2021, 9, e003334.		101
239	<sc>MyD88</sc> in myofibroblasts regulates aerobic glycolysisâ€driven hepatocarcinogenesis via <sc>ERK</sc>-dependent <sc>PKM2</sc> nuclear relocalization and activation. <i>Journal of Pathology</i> , 2022, 256, 414-426.	2.1	15
240	Genetic Landscape of Multistep Hepatocarcinogenesis. <i>Cancers</i> , 2022, 14, 568.	1.7	7

#	ARTICLE	IF	CITATIONS
241	BMP9-ID1 Signaling Activates HIF-1 α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1475.	1.8	14
242	Novel Risk Classification Based on Pyroptosis-Related Genes Defines Immune Microenvironment and Pharmaceutical Landscape for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 447.	1.7	3
243	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. <i>Frontiers in Oncology</i> , 2021, 11, 783339.	1.3	4
244	Novel protein kinase C phosphorylated kinase inhibitor-matine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal. <i>Bioengineered</i> , 2022, 13, 2851-2865.	1.4	6
245	Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-15.	0.6	2
246	The CRAFTY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy. <i>Journal of Hepatology</i> , 2022, 76, 1232-1233.	1.8	2
247	Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. <i>Science Advances</i> , 2022, 8, eabh2635.	4.7	35
248	Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria. <i>Liver Cancer International</i> , 0, , .	0.2	0
249	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. <i>World Journal of Gastroenterology</i> , 2022, 28, 310-331.	1.4	29
250	Structure-activity features of purines and their receptors: implications in cell physiopathology. <i>Molecular Biomedicine</i> , 2022, 3, 5.	1.7	8
251	Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2022, 13, 62-75.	1.2	3
252	ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 801506.	1.3	16
253	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 500.	1.8	37
254	Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. <i>Oncolmmunology</i> , 2022, 11, .	2.1	2
255	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. <i>Cancers</i> , 2022, 14, 621.	1.7	34
256	Mapping Intellectual Structure for the Long Non-Coding RNA in Hepatocellular Carcinoma Development Research. <i>Frontiers in Genetics</i> , 2021, 12, 771810.	1.1	5
257	Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period. <i>Hepatology International</i> , 2022, 16, 135-147.	1.9	1
258	EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 780509.	2.2	2

#	ARTICLE	IF	CITATIONS
259	State of the Art: Contrast Enhanced 4D Ultrasound to Monitor or Assess Locoregional Therapies. Digestive Disease Interventions, 2022, 06, 003-012.	0.3	0
260	circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c/p/methylated DNA-binding domain protein 2 axis. Clinical and Translational Medicine, 2022, 12, e662.	1.7	19
261	Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk. Lancet Oncology, The, 2022, 23, 14-16.	5.1	1
262	Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101869.	0.7	5
263	Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T lymphocyte infiltration in HCC through cGAS-STING pathway. Hepatology, 2023, 77, 33-47.	3.6	28
264	T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis. Cancers, 2022, 14, 604.	1.7	4
265	Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients. International Journal of Biological Sciences, 2022, 18, 360-373.	2.6	51
266	Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study. Contrast Media and Molecular Imaging, 2022, 2022, 1-8.	0.4	2
267	Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 257-273.	8.2	77
268	Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. Cancers, 2022, 14, 427.	1.7	3
269	Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-12.	0.8	0
270	Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology, 2022, 86, 799-815.	4.3	28
271	Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 761046.	2.2	19
272	Prediction of Hepatocellular Carcinoma Prognosis and Immune Cell Infiltration Using Gene Signature Associated with Inflammatory Response. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-24.	0.7	2
273	Modifying ¹⁸ F-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study. Journal of Magnetic Resonance Imaging, 2022, 56, 399-412.	1.9	6
274	Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma. Cancers, 2022, 14, 402.	1.7	6
275	(α)-Agelasidine A Induces Endoplasmic Reticulum Stress-Dependent Apoptosis in Human Hepatocellular Carcinoma. Marine Drugs, 2022, 20, 109.	2.2	10
276	Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Frontiers in Immunology, 2022, 13, 815575.	2.2	63

#	ARTICLE	IF	CITATIONS
277	Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. <i>Frontiers in Oncology</i> , 2021, 11, 835889.	1.3	32
278	Pt(II)-NHC Complex Induces ROS-ERS-Related DAMP Balance to Harness Immunogenic Cell Death in Hepatocellular Carcinoma. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1848-1866.	2.9	36
279	Validation of Software for Patient-Specific Real-Time Simulation of Hepatic Radiofrequency Ablation. <i>Academic Radiology</i> , 2022, , .	1.3	5
280	Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy. <i>ACS Nano</i> , 2022, 16, 897-909.	7.3	8
281	Identification of the critical genes and miRNAs in hepatocellular carcinoma by integrated bioinformatics analysis. <i>Medical Oncology</i> , 2022, 39, 21.	1.2	4
282	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. <i>Hepatology</i> , 2022, 76, 630-645.	3.6	13
283	Upregulation of TMCO3 Promoting Tumor Progression and Contributing to the Poor Prognosis of Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	1
284	Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382110706.	0.8	7
285	A Novel Lactate Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 801959.	1.8	23
286	Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 740-747.	0.7	7
287	Phosphoribosyl Pyrophosphate Amido Transferase: A New Prognostic Biomarker for Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 353-358.	0.8	1
288	Roles for the mycobiome in liver disease. <i>Liver International</i> , 2022, 42, 729-741.	1.9	16
289	Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?. <i>Journal of Hepatology</i> , 2022, 76, 975-980.	1.8	24
290	T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. <i>Hepatology</i> , 2022, 75, 1038-1049.	3.6	25
291	A randomized clinical trial of guided self-help intervention based on mindfulness for patients with hepatocellular carcinoma: effects and mechanisms. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 227-236.	0.6	5
294	Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. <i>Scientific Reports</i> , 2022, 12, 1449.	1.6	9
295	Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2022, 27, 100678.	0.6	5
297	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. <i>JHEP Reports</i> , 2022, 4, 100445.	2.6	6

#	ARTICLE	IF	CITATIONS
298	NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. <i>IScience</i> , 2022, 25, 103847.	1.9	12
299	MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View. <i>Diagnostics</i> , 2022, 12, 374.	1.3	9
300	The role of RNA binding proteins in hepatocellular carcinoma. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114114.	6.6	9
301	Fabrication of programmed photosensitizer-conjugated nanoassemblies by dual supramolecular self-assembly for photodynamic therapy of orthotopic hepatoma. <i>Chemical Engineering Journal</i> , 2022, 435, 134930.	6.6	8
302	Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury. <i>Materials Today Bio</i> , 2022, 13, 100215.	2.6	29
303	Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study. <i>Cancer Control</i> , 2022, 29, 107327482110515.	0.7	14
304	Identification Prognostic Value and Correlation with Tumor-Infiltrating Immune Cells of Tripartite-Motif Family Genes in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 1349-1363.	0.8	5
305	Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score. <i>Frontiers in Pharmacology</i> , 2021, 12, 819985.	1.6	9
306	miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. <i>Hepatology Communications</i> , 2022, 6, 1467-1481.	2.0	8
307	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. <i>Journal of Hepatology</i> , 2022, 77, 116-127.	1.8	40
308	Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application. <i>ACS Synthetic Biology</i> , 2022, , .	1.9	1
309	The effectiveness of Radiofrequency Ablation for Patients with BCLC B1 Stage Hepatocellular Carcinoma downgraded by Transarterial Chemoembolization. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, , 101878.	0.7	0
310	Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1926.	1.8	1
311	Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. <i>Cancers</i> , 2022, 14, 828.	1.7	15
312	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 405-412.	0.9	35
313	Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-vaccine Efficiency. <i>Advanced Science</i> , 2022, 9, e2105631.	5.6	51
314	An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2046-2058.	0.6	2
315	The Translational Bridge between Inflammation and Hepatocarcinogenesis. <i>Cells</i> , 2022, 11, 533.	1.8	9

#	ARTICLE	IF	CITATIONS
316	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	1.8	139
317	Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways. <i>Toxicology and Applied Pharmacology</i> , 2022, 438, 115911.	1.3	6
318	Immunotherapies for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2022, 11, 571-591.	1.3	29
319	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	1.3	21
320	Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13627.	1.8	16
321	Novel Perspectives towards RNA-Based Nano-Theranostic Approaches for Cancer Management. <i>Nanomaterials</i> , 2021, 11, 3330.	1.9	33
322	Identification and validation of the N6-methyladenosine RNA methylation regulator ZC3H13 as a novel prognostic marker and potential target for hepatocellular carcinoma. <i>International Journal of Medical Sciences</i> , 2022, 19, 618-630.	1.1	4
323	Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210853.	0.8	3
324	Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC Database. <i>Oncologie</i> , 2022, 24, 101-111.	0.2	5
325	Adaptive Multimodal Fusion With Attention Guided Deep Supervision Net for Grading Hepatocellular Carcinoma. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 4123-4131.	3.9	8
326	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. <i>International Journal of Biological Sciences</i> , 2022, 18, 2775-2794.	2.6	27
327	Implications of genetic heterogeneity in hepatocellular cancer. <i>Advances in Cancer Research</i> , 2022, , 103-135.	1.9	5
328	Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. <i>Advances in Cancer Research</i> , 2022, , 319-341.	1.9	2
329	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
330	High Expression of Ferritinophagy-Related RRM2 Gene in Relation to Unfavorable Outcome and Immune Cells Infiltration in Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
331	A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, 95.	1.8	8
332	Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition. <i>Cancers</i> , 2022, 14, 910.	1.7	5
333	CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target. <i>Clinical and Translational Oncology</i> , 2022, 24, 1447-1458.	1.2	6

#	ARTICLE	IF	CITATIONS
334	The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 146.	2.7	11
335	Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	4
336	Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?. <i>Future Oncology</i> , 2022, , .	1.1	4
337	Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts. <i>PLoS ONE</i> , 2022, 17, e0264266.	1.1	2
338	Effects of exercise on high-fat diet-induced non-alcoholic fatty liver disease and lipid metabolism in ApoE knockout mice. <i>Nutrition and Metabolism</i> , 2022, 19, 10.	1.3	12
339	Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 4291-4303.	0.7	23
340	Role of nanoparticles in transarterial radioembolization with glass microspheres. <i>Annals of Nuclear Medicine</i> , 2022, 36, 479.	1.2	0
341	Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells. <i>Cancers</i> , 2022, 14, 1205.	1.7	4
342	Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells. <i>Cancers</i> , 2022, 14, 1204.	1.7	1
343	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
345	Ca ²⁺ Transportome and the Interorganelle Communication in Hepatocellular Carcinoma. <i>Cells</i> , 2022, 11, 815.	1.8	5
346	Ruptured Hepatocellular Carcinoma: Current Status of Research. <i>Frontiers in Oncology</i> , 2022, 12, 848903.	1.3	22
347	PKC β /ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 163-176.	1.8	52
348	ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	3
349	The Bright and the Dark Side of TGF- β ² Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. <i>Cancers</i> , 2022, 14, 940.	1.7	16
350	PD-L1 blockade liberates intrinsic antitumorigenic properties of glycolytic macrophages in hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 2551-2560.	6.1	36
351	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1154.	1.7	11
352	Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy. <i>Cancers</i> , 2022, 14, 1165.	1.7	6

#	ARTICLE	IF	CITATIONS
353	Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 836333.	1.3	1
354	Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?. <i>Seminars in Cancer Biology</i> , 2022, 86, 1175-1185.	4.3	2
355	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	6.1	90
356	Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 792676.	1.8	18
357	Aptamers and New Bioreceptors for the Electrochemical Detection of Biomarkers Expressed in Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2022, 29, 4363-4390.	1.2	2
358	Discovery of Novel Indazoles as Potent and Selective PI3K \hat{I} Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3849-3865.	2.9	9
359	Use of chemotherapy to treat hepatocellular carcinoma. <i>BioScience Trends</i> , 2022, 16, 31-45.	1.1	35
360	Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2022.	1.8	13
361	Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 2022, 28, e934936.	0.5	2
362	Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present. <i>Clinical Cancer Research</i> , 2022, 28, 2738-2743.	3.2	8
363	Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 233-263.	1.8	27
364	Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, 1372.	5.8	44
365	Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. <i>BMC Cancer</i> , 2022, 22, 335.	1.1	12
366	Newcastle Disease Virus/HK84: Next Potential Star for Targeted Immunotherapy of Hepatocellular Carcinoma?. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 179-180.	0.7	1
367	Downregulation of ZC3H13 by miR-362-3p/miR-425-5p is associated with a poor prognosis and adverse outcomes in hepatocellular carcinoma. <i>Aging</i> , 2022, 14, 2304-2319.	1.4	19
368	Anti-Cancer Activity of <i>Buthus occitanus</i> Venom on Hepatocellular Carcinoma in 3D Cell Culture. <i>Molecules</i> , 2022, 27, 2219.	1.7	2
369	Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma. <i>Hepatology International</i> , 2022, 16, 371-380.	1.9	5
370	Tumour endothelial cells for translational research and therapeutics. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0

#	ARTICLE	IF	CITATIONS
371	Complete response after combined chemoembolization and Huaier therapy for pulmonary metastasis of Hepatocellular carcinoma: A case report. <i>Asian Journal of Surgery</i> , 2022, 45, 1589-1589.	0.2	0
372	IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 746643.	1.3	4
373	Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	2
374	Laparoscopic Liver Resection for Hepatocellular Carcinoma. , 0, , .		0
375	Hyperpolarized carbon 13 MRI in liver diseases: Recent advances and future opportunities. <i>Liver International</i> , 2022, 42, 973-983.	1.9	7
376	Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100335.	1.5	9
377	The potential value of plasma Circ-ITCH in hepatocellular carcinoma patients with current hepatitis C virus infection. <i>GastroenterologÃa Y HepatologÃa</i> , 2023, 46, 17-27.	0.2	1
378	The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update. <i>Biomolecules</i> , 2022, 12, 462.	1.8	14
379	Image-matching digital macro-slideâ€”a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma. <i>Hepatology International</i> , 2022, 16, 381-395.	1.9	6
380	A microenvironment-responsive FePt probes for imaging-guided Fenton-enhanced radiotherapy of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, 100.	4.2	7
381	The Fight against Cancer by Microgravity: The Multicellular Spheroid as a Metastasis Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3073.	1.8	32
382	Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 98.	3.5	43
383	Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. <i>Hepatology International</i> , 2022, 16, 412-422.	1.9	2
384	Lipid alterations in chronic liver disease and liver cancer. <i>JHEP Reports</i> , 2022, 4, 100479.	2.6	69
385	Unique molecular characteristics of NAFLD-associated liver cancer accentuate Î²-catenin/TNFRSF19-mediated immune evasion. <i>Journal of Hepatology</i> , 2022, 77, 410-423.	1.8	13
386	AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 853652.	1.8	4
387	ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 842351.	1.1	8
388	LIF-ting ferroptosis to improve liver cancer therapy. <i>Genes and Diseases</i> , 2022, 9, 1153-1155.	1.5	3

#	ARTICLE	IF	CITATIONS
389	Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 98-120.	2.0	12
390	Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System. <i>Molecules</i> , 2022, 27, 2082.	1.7	3
391	Nanoliposome C6â€Ceramide in combination with antiâ€CTLA4 antibody improves antiâ€tumor immunity in hepatocellular cancer. <i>FASEB Journal</i> , 2022, 36, e22250.	0.2	10
392	JAKâ€STAT core cancer pathway: An integrative cancer interactome analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2049-2062.	1.6	32
393	Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2022, 77, 453-466.	1.8	50
394	The clinical value of dualâ€energy computed tomography and diffusionâ€weighted imaging in the context of liver cancer: A narrative review. <i>Journal of Clinical Ultrasound</i> , 2022, 50, 862-868.	0.4	2
395	Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1536.	1.0	0
396	miRâ€374câ€5p regulates PTTG1 and inhibits cell growth and metastasis in hepatocellular carcinoma by regulating epithelialâ€mesenchymal transition. <i>Molecular Medicine Reports</i> , 2022, 25, .	1.1	3
398	A Novel Predictive Scoring System for 90-Day Mortality among Patients with Hepatocellular Cell Carcinoma Receiving Major Hepatectomy. <i>Cancers</i> , 2022, 14, 1398.	1.7	0
399	MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. <i>European Radiology</i> , 2022, , 1.	2.3	14
400	Expanding the immunotherapy roadmap for hepatocellular carcinoma. <i>Cancer Cell</i> , 2022, 40, 252-254.	7.7	9
401	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1526.	1.7	7
402	Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching. <i>BMC Surgery</i> , 2022, 22, 103.	0.6	4
404	Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 1806-1814.	2.9	11
405	pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2122310119.	3.3	16
406	Synthesis, and docking studies of novel heterocycles incorporating the indazolylthiazole moiety as antimicrobial and anticancer agents. <i>Scientific Reports</i> , 2022, 12, 3424.	1.6	15
407	Kindlin-2â€miR-1258â€TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis. <i>Journal of Gastroenterology</i> , 2022, 57, 372-386.	2.3	5
408	CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 755-771.	2.0	38

#	ARTICLE	IF	CITATIONS
409	Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: a systematic review and diagnostic test accuracy meta-analysis.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101909.	0.7	1
410	Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study. <i>Cancers</i> , 2022, 14, 1568.	1.7	9
411	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 821903.	1.3	2
412	Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma. <i>Virology Journal</i> , 2022, 19, 44.	1.4	7
413	Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 834606.	2.2	6
414	Recent Advances in Glycyrrhetic Acid-Functionalized Biomaterials for Liver Cancer-Targeting Therapy. <i>Molecules</i> , 2022, 27, 1775.	1.7	21
415	An emerging role of radiation-induced exosomes in hepatocellular carcinoma progression and radioresistance (Review). <i>International Journal of Oncology</i> , 2022, 60, .	1.4	7
416	Rcl1 suppresses tumor progression of hepatocellular carcinoma: a comprehensive analysis of bioinformatics and in vitro experiments. <i>Cancer Cell International</i> , 2022, 22, 114.	1.8	2
417	EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma. <i>Journal of Molecular Medicine</i> , 2022, 100, 629-643.	1.7	6
418	The Functional Roles of Immune Cells in Primary Liver Cancer. <i>American Journal of Pathology</i> , 2022, 192, 826-836.	1.9	17
419	Letter to the editor: GALAD score: Superior surveillance strategy or not?. <i>Hepatology</i> , 2022, 76, E38-E39.	3.6	1
420	Medicaid expansion is associated with a higher likelihood of early diagnosis, resection, transplantation, and overall survival in patients with hepatocellular carcinoma. <i>Hpb</i> , 2022, 24, 1482-1491.	0.1	11
421	SLC35B4 Stabilizes c-MYC Protein by O-GlcNAcylation in HCC. <i>Frontiers in Pharmacology</i> , 2022, 13, 851089.	1.6	5
422	ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma. <i>Cancer Letters</i> , 2022, , 215640.	3.2	9
423	Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
424	A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2022, 77, 632-641.	1.8	19
425	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2449-2460.	3.2	39
426	GALAD Score for HCC Screening and Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 556-557.	2.4	6

#	ARTICLE	IF	CITATIONS
427	Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 521-530.	5.1	116
428	Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 774335.	1.8	15
429	Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Cureus</i> , 2022, 14, e23783.	0.2	1
430	RBM24 in the Post-Transcriptional Regulation of Cancer Progression: Anti-Tumor or Pro-Tumor Activity?. <i>Cancers</i> , 2022, 14, 1843.	1.7	5
431	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. <i>Journal of Hepatology</i> , 2022, 77, 748-760.	1.8	57
432	Sertralin ve sorafenibin karaciğer kanseri hücrelerinde P-glikoprotein gen ekspresyonuna ve rodamin 123 birikimine etkileri. <i>Mersin Üniversitesi Sağlık Bilimleri Dergisi</i> , 0, , 56-65.	0.2	0
433	Harnessing Rift Valley fever virus NSs gene for cancer gene therapy. <i>Cancer Gene Therapy</i> , 2022, 29, 1477-1486.	2.2	2
434	Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 864106.	1.3	6
435	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114
436	Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1752-1763.	1.9	3
437	Immunotherapy for hepatocellular carcinoma: a CRAFTY approach to patient stratification. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 327-329.	0.7	1
438	Total-body [18F]FDG PET/CT scan has stepped into the arena: the faster, the better. Is it always true?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3322-3327.	3.3	9
439	Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101853.	0.7	6
440	The CpG Island-Binding Protein SAMD1 Contributes to an Unfavorable Gene Signature in HepG2 Hepatocellular Carcinoma Cells. <i>Biology</i> , 2022, 11, 557.	1.3	5
441	ROS-mediated activation of p38 protects hepatocellular carcinoma cells from caspase-independent death elicited by lysosomal damage. <i>Biochemical Pharmacology</i> , 2022, 198, 114983.	2.0	5
442	Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. <i>BMJ Open</i> , 2022, 12, e059779.	0.8	1
443	Attention guided discriminative feature learning and adaptive fusion for grading hepatocellular carcinoma with Contrast-enhanced MR. <i>Computerized Medical Imaging and Graphics</i> , 2022, 97, 102050.	3.5	4
444	GNL3 Regulates SIRT1 Transcription and Promotes Hepatocellular Carcinoma Stem Cell-Like Features and Metastasis. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	0

#	ARTICLE	IF	CITATIONS
445	Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 273-288.	1.8	5
446	Emerging immunotherapy for HCC: A guide for hepatologists. <i>Hepatology</i> , 2022, 75, 1604-1626.	3.6	97
447	miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. <i>Pathology Research and Practice</i> , 2022, 233, 153886.	1.0	53
448	Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. <i>European Journal of Cancer</i> , 2022, 166, 176-184.	1.3	26
449	Liver transplantation for Hepatocellular Carcinoma: A prognostic model incorporating pretransplant inflammatory cytokines. <i>Cytokine</i> , 2022, 153, 155847.	1.4	2
450	Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. <i>Neoplasia</i> , 2022, 28, 100788.	2.3	22
451	Multi-material basis and multi-mechanisms of the Dahuang Zhechong pill for regulating Treg/Th1 balance in hepatocellular carcinoma. <i>Phytomedicine</i> , 2022, 100, 154055.	2.3	10
452	Boosting ferroptosis via abplatin(iv) for treatment of platinum-resistant recurrent ovarian cancer. <i>Nano Today</i> , 2022, 44, 101459.	6.2	17
453	The Emerging Role of PIWI-Interacting RNAs (piRNAs) in Gastrointestinal Cancers: An Updated Perspective. <i>Cancers</i> , 2022, 14, 202.	1.7	17
454	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study. <i>Frontiers in Oncology</i> , 2021, 11, 781029.	1.3	3
455	Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2021, 27, 1610075.	0.9	8
456	Deep learning in hepatocellular carcinoma: Current status and future perspectives. <i>World Journal of Hepatology</i> , 2021, 13, 2039-2051.	0.8	21
457	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	4.2	25
458	Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations. <i>Cancers</i> , 2022, 14, 103.	1.7	14
459	Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 1-3.	0.4	1
460	Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13073.	1.8	10
461	KIAA1217 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinoma Metastasis by Interacting with and Activating STAT3. <i>International Journal of Molecular Sciences</i> , 2022, 23, 104.	1.8	9
462	Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 6307.	1.7	17

#	ARTICLE	IF	CITATIONS
463	Tobacco Smoking and Liver Cancer Risk: Potential Avenues for Carcinogenesis. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	37
464	Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. <i>Frontiers in Endocrinology</i> , 2021, 12, 808526.	1.5	24
465	A targetable LIFR~NF-ÎB~LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. <i>Nature Communications</i> , 2021, 12, 7333.	5.8	117
466	The Emerging Role of Ferroptosis in Liver Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 801365.	1.8	30
467	Liquid~Liquid Phase Separation-Related Genes Associated with Tumor Grade and Prognosis in Hepatocellular Carcinoma: A Bioinformatic Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9671-9679.	0.8	5
468	HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	3
469	ENO3 Inhibits Growth and Metastasis of Hepatocellular Carcinoma via Wnt/Î2-Catenin Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 797102.	1.8	14
470	Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 781307.	1.6	10
471	Construction and Validation of a Combined Ferroptosis and Hypoxia Prognostic Signature for Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 809672.	1.6	12
472	Immunological alterations after immunotherapy with short lived HBV~TCR T cells associates with long~term treatment response in HBV~HCC. <i>Hepatology Communications</i> , 2022, 6, 841-854.	2.0	7
473	Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 750084.	1.8	3
474	Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. <i>Frontiers in Immunology</i> , 2021, 12, 792781.	2.2	39
475	A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. <i>Frontiers in Oncology</i> , 2021, 11, 788635.	1.3	9
476	Controlling cholesterol entry into mitochondria, a key step for hepatocarcinogenesis in non-alcoholic steatohepatitis-related hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 890-892.	0.7	1
477	Mesenchymal stem cell-derived exosomes for gastrointestinal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1981-1996.	0.8	10
478	GOLT1B Activation in Hepatitis C Virus-Infected Hepatocytes Links ER Trafficking and Viral Replication. <i>Pathogens</i> , 2022, 11, 46.	1.2	0
479	AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13247.	1.8	4
480	Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2818-2825.e1.	2.4	26

#	ARTICLE	IF	CITATIONS
481	Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism. <i>Cells</i> , 2021, 10, 3469.	1.8	6
482	A Novel Blood Index-Based Model to Predict Hepatitis B Virus-Associated Hepatocellular Carcinoma Recurrence After Curative Hepatectomy: Guidance on Adjuvant Transcatheter Arterial Chemoembolization Choice. <i>Frontiers in Oncology</i> , 2021, 11, 755235.	1.3	4
483	CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. <i>Gastroenterology & Hepatology</i> , 2022, 45, 742-752.	0.2	6
484	p62/SQSTM1 in liver diseases: the usual suspect with multifarious identities. <i>FEBS Journal</i> , 2023, 290, 892-912.	2.2	15
486	<scp>BCL10</scp> correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma. <i>IUBMB Life</i> , 2021, , .	1.5	1
487	Influence of schisantherin A on the pharmacokinetics of lenvatinib in rats and its potential mechanism. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 802-811.	0.6	1
488	Copper Isotope Evidence of Oxidative Stressâ€“Induced Hepatic Breakdown and the Transition to Hepatocellular Carcinoma. , 2022, 1, 480-486.		5
489	Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance. <i>Korean Journal of Radiology</i> , 2022, 23, 598.	1.5	6
490	Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab. <i>Frontiers in Oncology</i> , 2022, 12, 848129.	1.3	3
491	Fingolimod exerts <i>in vitro</i> anticancer activity against hepatocellular carcinoma cell lines <i>via</i> YAP/TAZ suppression. <i>Acta Pharmaceutica</i> , 2022, 72, 427-436.	0.9	1
492	Liver transplantation for malignant liver tumors. , 2022, 1, 3-11.		4
493	Uncovering N4-Acetylcytidine-Related mRNA Modification Pattern and Landscape of Stemness and Immunity in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 861000.	1.8	9
494	Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 857060.	1.6	3
495	Leaping the Boundaries in Laparoscopic Liver Surgery for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2012.	1.7	9
496	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	3.2	32
497	Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4477.	1.8	3
498	Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). <i>Cancers</i> , 2022, 14, 2061.	1.7	13
499	Determinants of Survival and Post-Progression Outcomes by Sorafenibâ€“Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2014.	1.7	5

#	ARTICLE	IF	CITATIONS
500	Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model. <i>Nanomaterials</i> , 2022, 12, 1364.	1.9	3
501	Evaluation of perfusion CT and dual-energy CT for predicting microvascular invasion of hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2022, 47, 2115-2127.	1.0	11
502	Identification and Validation of Hub Genes with Poor Prognosis in Hepatocellular Carcinoma by Integrated Bioinformatical Analysis. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3933-3941.	0.8	2
503	Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 595-604.	1.1	7
504	Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. <i>Frontiers in Public Health</i> , 2022, 10, 869960.	1.3	12
505	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	3.2	8
506	Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: A meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101930.	0.7	0
507	Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis. <i>Frontiers of Medicine</i> , 2022, 16, 216-226.	1.5	15
508	Systemic Therapy in Metastatic Hepatocellular Carcinoma. <i>Current Gastroenterology Reports</i> , 2022, 24, 65-71.	1.1	4
509	Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, 11, 3612-3622.	1.3	13
510	Construction of a Necroptosis-Related miRNA Signature for Predicting the Prognosis of Patients With Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 825261.	1.1	6
511	Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. <i>Biology</i> , 2022, 11, 585.	1.3	5
512	Combined Levo-tetrahydropalmatine and diphenylethylideneiodonium chloride enhances antitumor activity in hepatocellular carcinoma. <i>Pharmacological Research</i> , 2022, 179, 106219.	3.1	4
513	Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-21.	0.6	0
514	Targeting TGF- β 2 signal transduction for fibrosis and cancer therapy. <i>Molecular Cancer</i> , 2022, 21, 104.	7.9	222
515	TFAM loss induces nuclear actin assembly upon mDia2 malonylation to promote liver cancer metastasis. <i>EMBO Journal</i> , 2022, 41, e110324.	3.5	24
516	Outcomes and recurrence patterns following curative hepatectomy for hepatocellular carcinoma patients with different China liver cancer staging.. <i>American Journal of Cancer Research</i> , 2022, 12, 907-921.	1.4	0
517	Decoding the functional role of extracellular vesicles in hepatocellular carcinoma: implications in clinical theranostics. , 2022, , 301-339.		0

#	ARTICLE	IF	CITATIONS
518	Chemotherapy for hepatocellular carcinoma—an updated review. , 2022, , 351-363.		0
519	Deficient DNASE1L3 facilitates neutrophil extracellular traps-induced invasion via cyclic GMP&CAMP synthase and the non-canonical NF&B pathway in diabetic hepatocellular carcinoma. <i>Clinical and Translational Immunology</i> , 2022, 11, e1386.	1.7	7
520	A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection. <i>Diagnostics</i> , 2022, 12, 1073.	1.3	6
521	Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. <i>Cells</i> , 2022, 11, 1475.	1.8	16
522	High Expression of TGF- β 1 Contributes to Hepatocellular Carcinoma Prognosis via Regulating Tumor Immunity. <i>Frontiers in Oncology</i> , 2022, 12, 861601.	1.3	9
524	A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	3
525	Multi-Region Radiomic Analysis Based on Multi-Sequence MRI Can Preoperatively Predict Microvascular Invasion in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 818681.	1.3	9
526	Advanced hepatocellular carcinoma: Impact of systemic treatments on health-related quality of life and patient-reported outcomes. <i>Liver Cancer International</i> , 0, , .	0.2	1
527	In vitro and in vivo study: Ethanolic extract leaves of <i>Azadirachta indica</i> Juss. variant of Indonesia and Philippines suppresses tumor growth of hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling. <i>F1000Research</i> , 0, 11, 477.	0.8	0
528	Comprehensive Analysis of the Correlation Between Pyroptosis-Related lncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 867627.	1.1	12
530	Child-Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib. <i>Journal of Clinical Medicine</i> , 2022, 11, 2550.	1.0	3
531	Critical involvement of circular RNAs in virus-associated cancers. <i>Genes and Diseases</i> , 2023, 10, 2296-2305.	1.5	3
532	Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-6.	0.8	4
533	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	44
534	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2022, 14, 2396.	1.7	8
535	A New Inflammation-Related Risk Model for Predicting Hepatocellular Carcinoma Prognosis. <i>BioMed Research International</i> , 2022, 2022, 1-33.	0.9	3
536	Liver cancer cells with nuclear MET overexpression release translation regulatory protein-enriched extracellular vesicles exhibit metastasis promoting activity. , 2022, 1, .		0
537	EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 164.	3.5	24

#	ARTICLE	IF	CITATIONS
538	Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the \hat{I}^3 -Glutamyl Transpeptidase-to-Albumin Ratio. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1619-1627.	0.9	2
539	<scp>DDX55</scp> promotes hepatocellular carcinoma progression by interacting with <scp>BRD4</scp> and participating in exosome-mediated cell-cell communication. <i>Cancer Science</i> , 2022, 113, 3002-3017.	1.7	8
540	Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	25
541	Spiropachysine A suppresses hepatocellular carcinoma proliferation by inducing methuosis in vitro and in vivo. <i>Phytomedicine</i> , 2022, 102, 154151.	2.3	5
542	Artemyrianosins A-J, cytotoxic germacrane-type sesquiterpene lactones from <i>Artemisia myriantha</i> . <i>Natural Products and Bioprospecting</i> , 2022, 12, 16.	2.0	1
543	Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 738.	1.1	2
544	Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2022, 194, 1075-1086.	0.7	7
545	Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma. <i>Pharmacological Research</i> , 2022, 180, 106244.	3.1	13
546	PA2G4 promotes the metastasis of hepatocellular carcinoma by stabilizing FYN mRNA in a YTHDF2-dependent manner. <i>Cell and Bioscience</i> , 2022, 12, 55.	2.1	17
547	A novel four-gene signature for predicting the prognosis of hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1227-1237.	0.6	5
548	\hat{I}^2 -Patchoulene represses hypoxia-induced proliferation and epithelial-mesenchymal transition of liver cancer cells. <i>Bioengineered</i> , 2022, 13, 11907-11922.	1.4	4
549	Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2022, Volume 14, 1627-1639.	0.9	0
550	YES, a novel therapeutic target in hepatocellular carcinoma. <i>Molecular and Cellular Oncology</i> , 2022, 9, 2069993.	0.3	1
551	Early detection of hepatocellular carcinoma: roadmap for improvement. <i>Expert Review of Anticancer Therapy</i> , 2022, , 1-12.	1.1	1
552	Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 3, 100108.	0.5	2
553	HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer. <i>Life Sciences</i> , 2022, 301, 120620.	2.0	10
554	ALYREF associated with immune infiltration is a prognostic biomarker in hepatocellular carcinoma. <i>Translational Oncology</i> , 2022, 21, 101441.	1.7	5
555	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126

#	ARTICLE	IF	CITATIONS
556	Polyphenol Content, Antioxidant, Cytotoxic, and Genotoxic Activities of Bombax ceiba Flowers in Liver Cancer Cells Huh7. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1345-1350.	0.5	1
557	Identification of potential prognostic biomarkers for hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 812-821.	0.6	3
558	Identification of Context-Specific Fitness Genes Associated With Metabolic Rearrangements for Prognosis and Potential Treatment Targets for Liver Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
559	A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2022, 11, 5079-5096.	1.3	17
560	Lestaurtinib Has the Potential to Inhibit the Proliferation of Hepatocellular Carcinoma Uncovered by Bioinformatics Analysis and Pharmacological Experiments. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	1
561	UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response. <i>Biochemical and Biophysical Research Communications</i> , 2022, 613, 207-213.	1.0	3
562	High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. <i>Genes</i> , 2022, 13, 876.	1.0	5
563	Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 724-735.	3.7	47
564	Nutrition-Related Indicators in Patients with Liver Cancer: Application and Research Progress. <i>Advances in Clinical Medicine</i> , 2022, 12, 4005-4012.	0.0	0
565	Integrated Analysis Reveals Critical Ferroptosis Regulators and FTL Contribute to Cancer Progression in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	9
566	Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1197-1206.	1.4	13
567	The Efficacy and Safety of Transarterial Chemoembolization Plus Iodine 125 Seed Implantation in the Treatment of Hepatocellular Carcinoma With Oligometastases: A Case Series Reports. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
568	Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
569	MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF. <i>Cancer Cell International</i> , 2022, 22, 192.	1.8	4
570	Targeted Molecular Imaging Probes Based on Magnetic Resonance Imaging for Hepatocellular Carcinoma Diagnosis and Treatment. <i>Biosensors</i> , 2022, 12, 342.	2.3	7
571	ApoM regulates PFKL through the transcription factor SREBF1 to inhibit the proliferation, migration and metastasis of liver cancer cells. <i>Oncology Letters</i> , 2022, 24, .	0.8	2
572	Human liver single nucleus and single-cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. <i>Genome Medicine</i> , 2022, 14, 50.	3.6	27
573	Responsive Hydrogels Based on Triggered Click Reactions for Liver Cancer. <i>Advanced Materials</i> , 2022, 34, e2201651.	11.1	28

#	ARTICLE	IF	CITATIONS
574	Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210972.	0.8	0
575	Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2022, 13, 779691.	2.2	100
576	Association between CTLA-4 Gene Polymorphism and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 896-899.	0.1	0
577	Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. <i>World Journal of Hepatology</i> , 2022, 14, 957-972.	0.8	0
578	Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
579	Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-14.	1.1	1
580	Ejercicio f�sico y el riesgo de c�ncer hep�tico. <i>Revista Cient�fica Ciencias De La Salud</i> , 2022, 4, 24-37.	0.1	0
581	Correlation of CT Perfusion Parameters and Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (BFGF) in Patients with Primary Liver Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-5.	0.5	2
582	Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2022, 14, 885-895.	0.8	6
583	Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma. <i>FASEB Journal</i> , 2022, 36, .	0.2	12
584	Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
585	Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 221-230.	0.4	10
586	The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	17
587	Effect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
588	Members of the Chromobox Family Have Prognostic Value in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	3
589	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
590	Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma. <i>Materials</i> , 2022, 15, 3893.	1.3	9
591	A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. <i>FASEB Journal</i> , 2022, 36, .	0.2	17

#	ARTICLE	IF	CITATIONS
592	Novel Paired Cell Lines for the Study of Lipid Metabolism and Cancer Stemness of Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
593	Identification of an Endoplasmic Reticulum Stress-Related Gene Signature to Evaluate the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
594	HIF-1/2-Activated RNF146 Enhances the Proliferation and Glycolysis of Hepatocellular Carcinoma Cells via the PTEN/AKT/mTOR Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	5
595	Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, .	1.4	5
596	<scp>SREBF2âš</scp> axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. <i>Cancer Science</i> , 2023, 114, 477-489.	1.7	8
597	Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection. <i>Cancers</i> , 2022, 14, 2662.	1.7	6
598	Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
599	Hepatitis B Virus Infection among Japanese Immigrants and Descendants: The Need to Strengthen Preventive and Control Measures. <i>Viruses</i> , 2022, 14, 1085.	1.5	1
600	Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. <i>World Journal of Hepatology</i> , 2022, 14, 956-971.	0.8	3
601	The âš-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
602	Bioactive xanthenes, benzophenones and biphenyls from mangosteen root with potential anti-migration against hepatocellular carcinoma cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
603	Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 238-249.	0.4	5
604	Ferroptosis at the crossroads of tumor-host interactions, metastasis, and therapy response. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C95-C103.	2.1	8
605	Designing optimal allocations for cancer screening using queuing network models. <i>PLoS Computational Biology</i> , 2022, 18, e1010179.	1.5	1
606	Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 559-568.	0.6	13
607	A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
608	Burden of All Cancers Along With Attributable Risk Factors in China From 1990 to 2019: Comparison With Japan, European Union, and USA. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	3
609	Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	2

#	ARTICLE	IF	CITATIONS
610	Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2022, 17, e0269249.	1.1	2
611	Extracellular Vesicles and Hepatocellular Carcinoma: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
612	Antitumor Properties of a New Macrocyclic Tetranuclear Oxidovanadium(V) Complex with 3-Methoxysalicylidervaline Ligand. <i>Biomedicines</i> , 2022, 10, 1217.	1.4	1
613	Systematic Characterization of the Disruption of Intestine during Liver Tumor Progression in the xmrk Oncogene Transgenic Zebrafish Model. <i>Cells</i> , 2022, 11, 1810.	1.8	0
614	Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study. <i>World Journal of Clinical Oncology</i> , 2022, 13, 352-365.	0.9	5
615	Diagnostic performance of clusterin in hepatocellular carcinoma: A meta-analysis. <i>International Journal of Biological Markers</i> , 2022, 37, 404-411.	0.7	3
616	Integrative Analysis Identifies Cell-Type-Specific Genes Within Tumor Microenvironment as Prognostic Indicators in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
617	Analysis of multiple databases identifies crucial genes correlated with prognosis of hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
618	Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 1038-1046.	1.8	17
619	Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. <i>World Journal of Gastroenterology</i> , 2022, 28, 2251-2281.	1.4	23
620	Integrated transcriptome and in vitro analysis revealed anti-proliferative effect of sodium perborate on hepatocellular carcinoma cells. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, , 127011.	1.5	1
621	A pyroptosis-related gene signature predicts prognosis and immune microenvironment in hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
622	Emerging drugs for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 141-149.	1.0	4
624	Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
625	NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-17.	1.9	4
626	Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
627	Synergistic antitumor effects of compound-composed optimal formula from Aidi injection on hepatocellular carcinoma and colorectal cancer. <i>Phytomedicine</i> , 2022, 103, 154231.	2.3	7
628	Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
629	Hypoxia-inducible factors: cancer progression and clinical translation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	148
630	Identification of exosomal hsa-miR-483-5p as a potential biomarker for hepatocellular carcinoma via microRNA expression profiling of tumor-derived exosomes. <i>Experimental Cell Research</i> , 2022, 417, 113232.	1.2	11
631	Differentiating HCC from ICC and Prediction of ICC Grade Based on MRI Radiomics: Using Lesions and Their Extended Regions. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
632	Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 2335-2352.	3.3	16
633	Roles of circRNAs in the Tumorigenesis and Metastasis of HCC: A Mini Review. <i>Cancer Management and Research</i> , 0, Volume 14, 1847-1856.	0.9	3
634	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2022, 42, 188-201.	1.8	6
635	Role of IQ Motif-Containing GTPase-Activating Proteins in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
636	Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy. <i>Journal of Hepatology</i> , 2022, 77, 593-595.	1.8	5
637	Circulating <sc>microRNAs</sc> (<sc>miR</sc>â€16, <sc>miR</sc>â€22, <sc>miR</sc>â€122) expression and early diagnosis of hepatocellular carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	0.9	13
639	Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3â€cm in Size: A Multi-Center, Retrospective Study. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
640	An mALBI-Childâ€Pugh-based nomogram for predicting post-hepatectomy liver failure grade Bâ€C in patients with huge hepatocellular carcinoma: a multi-institutional study. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	5
641	Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. <i>Cancers</i> , 2022, 14, 2947.	1.7	9
642	Evaluating the state of the science for adeno-associated virus integration: An integrated perspective. <i>Molecular Therapy</i> , 2022, 30, 2646-2663.	3.7	65
643	SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ. <i>Hepatology</i> , 2023, 78, 103-119.	3.6	6
644	Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression. , 2022, 10, e004763.		19
645	Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancerâ€Current Treatment Options and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6664.	1.8	13
646	Cross Analysis of Genomic-Pathologic Features on Multiple Primary Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
648	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. <i>Hepatology International</i> , 2022, 16, 1150-1160.	1.9	35

#	ARTICLE	IF	CITATIONS
649	The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
650	Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1654-1665.	1.4	3
651	In-depth Profiling and Quantification of the Lysine Acetylome in Hepatocellular Carcinoma with a Trapped Ion Mobility Mass Spectrometer. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100255.	2.5	7
652	Diagnostic Value of Combined Detection via Protein Induced by Vitamin K Absence or Antagonist II, Alpha-Fetoprotein, and D-Dimer in Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 5763-5773.	0.8	4
654	Radiomic analysis based on multi-phase magnetic resonance imaging to predict preoperatively microvascular invasion in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 2733-2747.	1.4	4
655	Identifying interactions in omics data for clinical biomarker discovery using symbolic regression. <i>Bioinformatics</i> , 2022, 38, 3749-3758.	1.8	16
656	Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism. <i>Cancers</i> , 2022, 14, 2896.	1.7	13
657	Proton Therapy in the Management of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2900.	1.7	4
659	Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF- β 2, IL-1, and IL-6). <i>Hormone Molecular Biology and Clinical Investigation</i> , 2022, 43, 389-396.	0.3	0
660	Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
661	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
662	The promise of small particles: extracellular vesicles as biomarkers in liver pathology. <i>Journal of Physiology</i> , 0, , .	1.3	3
663	Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 2561-2568.	1.4	5
664	Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	9
665	Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 670-681.	8.2	106
666	Methyl Gallate Suppresses the Migration, Invasion, and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells via the AMPK/NF- κ B Signaling Pathway in vitro and in vivo. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
667	Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
668	The Chloroform Extracts of Vietnamese <i>Sophora flavescens</i> Ait. Inhibit the Proliferation of HepG2 Cells through Apoptosis Induction. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5906.	1.3	0

#	ARTICLE	IF	CITATIONS
669	A Superstable Homogeneous Lipiodol-Nanoformulation to Overcome the Dilemma of Interventional Embolization Chemotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	4
670	Hepatocellular Carcinoma in Africa: Challenges and Opportunities. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
671	High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
672	Recapitulating the liver niche in vitro. <i>Advances in Stem Cells and Their Niches</i> , 2022, , 1-55.	0.1	1
673	Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR ^{RA}) Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1648-1659.	2.9	31
674	A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
675	Prognostic Nutritional Index in Hepatocellular Carcinoma Patients With Hepatitis B Following US-Guided Percutaneous Microwave Ablation: A Retrospective Study With 1,047 Patients. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
676	Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 1035-1058.	0.9	4
677	Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma. <i>Cells</i> , 2022, 11, 2051.	1.8	7
678	Orthologs of human circulating miRNAs associated with hepatocellular carcinoma are elevated in mouse plasma months before tumour detection. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
679	Moving Away From a One-Size-Fits-All Approach to Hepatocellular Carcinoma Surveillance. <i>American Journal of Gastroenterology</i> , 2022, 117, 1409-1411.	0.2	2
680	Exosomal miR-4800-3p Aggravates the Progression of Hepatocellular Carcinoma via Regulating the Hippo Signaling Pathway by Targeting STK25. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
681	AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma. <i>Oncogene</i> , 2022, 41, 3846-3858.	2.6	11
682	miR-15a and miR-20b sensitize hepatocellular carcinoma cells to sorafenib through repressing CDC37L1 and consequent PPIA downregulation. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	8
683	Extract of <i>Marsdenia tenacissima</i> (Roxb.) Moon [Apocynaceae] Suppresses Hepatocellular Carcinoma by Inhibiting Angiogenesis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
684	FBXO9 Mediates the Cancer-Promoting Effects of ZNF143 by Degrading FBXW7 and Facilitates Drug Resistance in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
685	Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
686	Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. <i>OncoTargets and Therapy</i> , 0, Volume 15, 703-716.	1.0	2

#	ARTICLE	IF	CITATIONS
687	GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway. <i>Cancer Gene Therapy</i> , 0, , .	2.2	2
688	Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-10.	1.1	2
689	Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	6
690	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. <i>Cancers</i> , 2022, 14, 3213.	1.7	10
692	Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
693	Gene Co-Expression Network Analysis Identifies Hubs in Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Journal of the Chinese Medical Association</i> , 0, Publish Ahead of Print, .	0.6	3
694	A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
695	Spontaneous Regression of Hepatocellular Carcinoma From Autoinfarction and Implications on Liver Transplantation. <i>ACG Case Reports Journal</i> , 2022, 9, e00825.	0.2	0
696	Anticancer Effects and Mechanisms of Berberine from Medicinal Herbs: An Update Review. <i>Molecules</i> , 2022, 27, 4523.	1.7	26
697	TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial. <i>European Radiology</i> , 2022, 32, 7335-7343.	2.3	3
698	Suppressive Effects of Siegesbeckia orientalis Ethanolic Extract on Proliferation and Migration of Hepatocellular Carcinoma Cells through Promoting Oxidative Stress, Apoptosis and Inflammatory Responses. <i>Pharmaceuticals</i> , 2022, 15, 826.	1.7	1
699	An Analysis of Microwave Ablation Parameters for Treatment of Liver Tumors from the 3D-IRCADb-01 Database. <i>Biomedicines</i> , 2022, 10, 1569.	1.4	4
700	Ficolin-3 may act as a tumour suppressor by recognising O-GlcNAcylation site in hepatocellular carcinoma. <i>Medical Hypotheses</i> , 2022, , 110899.	0.8	0
701	STARD5 as a potential clinical target of hepatocellular carcinoma. , 2022, 39, .		3
702	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 995-1008.	5.1	237
703	Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy. <i>Cancer Medicine</i> , 0, , .	1.3	5
704	Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.2	0
705	<sc>LOXL3</sc> promoted hepatocellular carcinoma progression via promotion of Snail1/<sc>USP4</sc>-mediated epithelial-mesenchymal transition. <i>Environmental Toxicology</i> , 2022, 37, 2540-2551.	2.1	6

#	ARTICLE	IF	CITATIONS
706	Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus-related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
707	Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
708	Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
709	PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 3307-3320.	0.4	3
710	Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-10.	0.9	1
711	Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1036-1048.	3.7	9
712	Current Strategies of Photoacoustic Imaging Assisted Cancer Theragnostics toward Clinical Studies. <i>ACS Photonics</i> , 2022, 9, 2555-2578.	3.2	14
713	Diagnostic performance of CT versus MRI Liver Imaging Reporting and Data System category 5 for hepatocellular carcinoma: a systematic review and meta-analysis of comparative studies. <i>European Radiology</i> , 2022, 32, 6723-6729.	2.3	4
714	Identification and Validation of a Potential Stemness-Associated Biomarker in Hepatocellular Carcinoma. <i>Stem Cells International</i> , 2022, 2022, 1-18.	1.2	1
715	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. <i>Gut</i> , 2023, 72, 381-391.	6.1	19
716	Investigation of Functional Synergism of CENPF and FOXM1 Identifies POLD1 as Downstream Target in Hepatocellular Carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
717	Cellular Prion Protein Is Closely Associated with Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1635.	1.3	2
718	Tumor suppressor LHPP suppresses cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma cell lines. <i>Journal of Physiology and Biochemistry</i> , 2022, 78, 807-817.	1.3	5
719	DNA methylation fingerprint of hepatocellular carcinoma from tissue and liquid biopsies. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
720	¹⁸ F-FDG / ¹⁸ F-Choline Dual-Tracer PET Behavior and Tumor Differentiation in HepatoCellular Carcinoma. A Systematic Review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	9
721	The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
722	Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions. <i>Liver International</i> , 2022, 42, 2131-2144.	1.9	8
723	A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
724	Design, synthesis and antitumor evaluation of novel quinazoline analogs in hepatocellular carcinoma cell. <i>Journal of Molecular Structure</i> , 2022, 1268, 133718.	1.8	4
725	<scp>TRIM27&USP7</scp> complex promotes tumour progression via <scp>STAT3</scp> activation in human hepatocellular carcinoma. <i>Liver International</i> , 2023, 43, 194-207.	1.9	10
726	Network pharmacology-based study on apigenin present in the methanolic fraction of leaves extract of <i>Cestrum nocturnum</i> L. to uncover mechanism of action on hepatocellular carcinoma. , 2022, 39, .		4
727	Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 595-607.	1.8	1
728	Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma. <i>Radiographics</i> , 2022, 42, 1338-1357.	1.4	4
729	Impairment of perioperative activities of daily living is associated with poor prognosis following hepatectomy for hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2022, 126, 995-1002.	0.8	6
730	Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1553-1584.	1.2	6
731	Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies. <i>Cancers</i> , 2022, 14, 3455.	1.7	6
732	GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. <i>Cell Metabolism</i> , 2022, 34, 1151-1167.e7.	7.2	40
733	Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	7
734	Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2. <i>International Journal of Hyperthermia</i> , 2022, 39, 888-896.	1.1	6
735	Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage O/A hepatocellular carcinoma: A large-scale multicenter study. <i>Surgery</i> , 2022, 172, 1147-1155.	1.0	4
736	LncRNA-Associated Genetic Etiologies Are Shared between Type 2 Diabetes and Cancers in the UAE Population. <i>Cancers</i> , 2022, 14, 3313.	1.7	1
737	Response to letter entitled: Re: "Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial"™. <i>European Journal of Cancer</i> , 2022, , .	1.3	0
738	Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. <i>Annals of Hepatology</i> , 2022, 27, 100740.	0.6	1
739	Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
740	Advancements in the Alcohol-Associated Liver Disease Model. <i>Biomolecules</i> , 2022, 12, 1035.	1.8	2
741	A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 727-745.	8.2	47

#	ARTICLE	IF	CITATIONS
742	Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
743	Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 864-875.	4.5	7
744	CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
745	Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2022, 14, 1480-1494.	0.8	0
746	Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
747	Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	9
748	Iplimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3065-3073.	1.2	6
750	Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	25
751	Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	1.4	8
752	Systematic review and meta-analysis of acupuncture for pain caused by liver cancer. <i>World Journal of Traditional Chinese Medicine</i> , 2022, 8, 402.	0.9	9
753	Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211166.	1.4	7
754	The role of molecular pathology in the precision diagnosis and subclassification of hepatocellular carcinoma. <i>Universa Medicina</i> , 2022, 41, 194-206.	0.1	0
755	Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma. <i>Immunogenetics</i> , 0, , .	1.2	1
756	Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
757	Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. <i>Chinese Medicine</i> , 2022, 17, .	1.6	10
758	SLC38A6, regulated by EP300-mediated modifications of H3K27ac, promotes cell proliferation, glutamine metabolism and mitochondrial respiration in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2022, 43, 885-894.	1.3	6
759	WWP2 overexpression inhibits the antitumor effects of doxorubicin in hepatocellular carcinoma. <i>Cell Biology International</i> , 2022, 46, 1682-1692.	1.4	6
760	Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. <i>World Journal of Gastroenterology</i> , 2022, 28, 3573-3585.	1.4	4

#	ARTICLE	IF	CITATIONS
761	Active ingredients and molecular targets of <i>Taraxacum mongolicum</i> against hepatocellular carcinoma: network pharmacology, molecular docking, and molecular dynamics simulation analysis. <i>PeerJ</i> , 0, 10, e13737.	0.9	4
762	Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. <i>Kreativna Ć Hirurģi Ć I Onkologi Ć</i> , 2022, 12, 139-150.	0.1	2
763	[¹⁸ F]-(2S,4R)4-Fluoroglutamine PET Imaging of Glutamine Metabolism in Murine Models of Hepatocellular Carcinoma (HCC). <i>Molecular Imaging</i> , 2022, 2022, .	0.7	1
764	Effectiveness of Porous Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Solitary Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2022, 42, 3947-3951.	0.5	1
765	CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
766	How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
767	Histological Severity of Cirrhosis Influences Surgical Outcomes of Hepatocellular Carcinoma After Curative Hepatectomy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 633-647.	1.8	3
768	Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8112.	1.8	6
769	Tumor immune microenvironment modulation by cholesterol in hepatocellular carcinoma. , 0, , 21-39.		1
770	Connexin32 regulates expansion of liver cancer stem cells via the PI3K/Akt signaling pathway. <i>Oncology Reports</i> , 2022, 48, .	1.2	1
771	Association of Heavy Alcohol Intake and <i>ALDH2</i> rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis. <i>JAMA Network Open</i> , 2022, 5, e2223511.	2.8	4
772	Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients. <i>Medicina (Lithuania)</i> , 2022, 58, 1015.	0.8	3
773	Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview. <i>World Journal of Gastroenterology</i> , 2022, 28, 4540-4556.	1.4	4
774	Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial. <i>Chinese Journal of Integrative Medicine</i> , 0, , .	0.7	0
775	Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma. <i>Liver Research</i> , 2022, , .	0.5	1
776	Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells. <i>Cancers</i> , 2022, 14, 4060.	1.7	1
777	E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription. <i>Molecular Carcinogenesis</i> , 2022, 61, 975-988.	1.3	4
778	Four-copy number alteration (CNA)-related lncRNA prognostic signature for liver cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
779	Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
780	Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	7
782	Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0
783	Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. <i>Journal of Hepatology</i> , 2022, 77, 1631-1641.	1.8	18
784	Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
785	Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review. <i>Liver Transplantation</i> , 2022, 28, 1865-1875.	1.3	6
786	Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 77, 1515-1524.	1.8	14
787	Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	2
788	Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents. <i>Clinical Cancer Research</i> , 2022, 28, 4509-4520.	3.2	3
789	Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4036.	1.7	5
790	Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma. <i>Nanomaterials</i> , 2022, 12, 2832.	1.9	2
791	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4051.	1.7	11
792	Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians. <i>World Journal of Hepatology</i> , 2022, 14, 1562-1575.	0.8	2
793	DNA methylation regulators-related molecular patterns and tumor immune landscape in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
794	Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis. <i>Hepatology</i> , 2023, 77, 1929-1942.	3.6	5
795	Hepatitis B Virus-Encoded HBsAg Contributes to Hepatocarcinogenesis by Inducing the Oncogenic Long Noncoding RNA LINC00665 through the NF- κ B Pathway. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
796	PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?. <i>Cancers</i> , 2022, 14, 4039.	1.7	16
797	Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2022, 39, 1097-1105.	1.1	5

#	ARTICLE	IF	CITATIONS
798	Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
799	Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer <i>in vitro</i> . <i>Oncology Letters</i> , 2022, 24, .	0.8	4
800	Effect of Transarterial Chemoembolization Plus Percutaneous Ethanol Injection or Radiofrequency Ablation for Liver Tumors. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 783-797.	1.8	3
801	Investigation of the long-term healing response of the liver to boiling histotripsy treatment <i>in vivo</i> . <i>Scientific Reports</i> , 2022, 12, .	1.6	5
802	M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
803	Constitutive Occurrence of E:N-cadherin Heterodimers in Adherens Junctions of Hepatocytes and Derived Tumors. <i>Cells</i> , 2022, 11, 2507.	1.8	4
804	Machine Learning-based Prediction of HBV-related Hepatocellular Carcinoma and Detection of Key Candidate Biomarkers. <i>Medeniyet Medical Journal</i> , 0, , .	0.4	1
805	Identification of G6PC as a potential prognostic biomarker in hepatocellular carcinoma based on bioinformatics analysis. <i>Medicine (United States)</i> , 2022, 101, e29548.	0.4	3
806	RNA binding protein PUM2 promotes hepatocellular carcinoma proliferation and apoptosis via binding to the 3'UTR of BTG3. <i>Oncology Letters</i> , 2022, 24, .	0.8	1
809	Role of pyroptosis in inflammation and cancer. , 2022, 19, 971-992.		155
810	Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. <i>World Journal of Gastroenterology</i> , 2022, 28, 3981-3993.	1.4	3
811	Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211152.	0.4	0
812	Interplay between fatty acids, SCD, mTORC1 and YAP/TAZ in promoting hepatocellular carcinoma. , 2022, , .		1
813	Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments. <i>Hepatology</i> , 2023, 77, 1566-1579.	3.6	15
815	SAC3D1 activates Wnt/ β -catenin signalling in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	2
816	Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
817	AN UNUSUAL CASE OF RECURRENT GASTROINTESTINAL BLEEDING AND ACUTE RENAL FAILURE-RELATED HEPATOCELLULAR CARCINOMA WITH GASTRIC OUTLET OBSTRUCTION. <i>Gastroenterology Nursing</i> , 2022, 45, 370-374.	0.2	0
818	NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	1

#	ARTICLE	IF	CITATIONS
819	Short- and long-term outcomes of laparoscopic versus open liver resection for large hepatocellular carcinoma: a propensity score study. <i>Surgery Today</i> , 0, , .	0.7	2
820	Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. <i>American Journal of Roentgenology</i> , 2023, 220, 245-255.	1.0	10
821	Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells. <i>Molecules and Cells</i> , 2022, 45, 550-563.	1.0	4
823	Management of Acute Coronary Syndrome With a Bleeding Intra-Tumoral Hepatocellular Carcinoma: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
824	Comprehensive analysis of nine m7G-related lncRNAs as prognosis factors in tumor immune microenvironment of hepatocellular carcinoma and experimental validation. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
825	The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
826	Current Imaging Diagnosis of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 3997.	1.7	21
827	Rare Inherited Cholestatic Disorders and Molecular Links to Hepatocarcinogenesis. <i>Cells</i> , 2022, 11, 2570.	1.8	2
828	Ethyl Acetate Fraction of <i>Hedyotis diffusa</i> Willd Induces Apoptosis via JNK/Nur77 Pathway in Hepatocellular Carcinoma Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-10.	0.5	0
829	Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1768.	2.0	2
830	Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma. , 2023, 2, 83-95.		6
831	Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-15.	0.7	3
832	Novel Radiolabeled TMTP1 for Long-Acting Hepatocellular Carcinoma Therapeutics. <i>Molecular Pharmaceutics</i> , 2022, 19, 3178-3186.	2.3	1
833	Roles and regulation of histone acetylation in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	8
834	The role of shear wave elastography in differentiation between benign and malignant portal vein thrombosis in hepatocellular carcinoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2022, 53, .	0.3	0
835	Biomechanical assessment of chronic liver injury using quantitative micro-elastography. <i>Biomedical Optics Express</i> , 2022, 13, 5050.	1.5	2
836	Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1918.	1.3	3
837	Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. , 0, , .		0

#	ARTICLE	IF	CITATIONS
838	Dysregulated FOXM1 signaling in the regulation of cancer stem cells. <i>Seminars in Cancer Biology</i> , 2022, 86, 107-121.	4.3	36
839	A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	3
840	Histological tumor micronecrosis in resected specimens after R0 hepatectomy for hepatocellular carcinomas is a factor in determining adjuvant TACE: A retrospective propensity score-matched study. <i>International Journal of Surgery</i> , 2022, 105, 106852.	1.1	7
841	Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 37356-37368.	4.0	7
842	Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virusâ€‘Sustained Virological Response Patients. <i>American Journal of Pathology</i> , 2022, 192, 1379-1396.	1.9	4
843	Differential diagnosis of hepatocellular carcinoma and hepatic hemangioma based on maximum wavelet-coefficient statistics: Novel radiomics features from plain CT. <i>Information Processing and Management</i> , 2022, 59, 103046.	5.4	2
844	Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 507 Td (cy Interactions, 2022, 365, 110066.	1.7	1
845	Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies. <i>International Journal of Surgery</i> , 2022, 105, 106821.	1.1	12
846	Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study. <i>International Journal of Surgery</i> , 2022, 105, 106843.	1.1	19
847	miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 538-549.	2.3	6
848	GPC3-targeted CART cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay. <i>Biochemistry and Biophysics Reports</i> , 2022, 31, 101324.	0.7	3
849	Polysome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy. <i>Journal of Controlled Release</i> , 2022, 350, 122-131.	4.8	4
850	LncRNA FIRRE promotes the proliferation and metastasis of hepatocellular carcinoma by regulating the expression of PXN through interacting with MBNL3. <i>Biochemical and Biophysical Research Communications</i> , 2022, 625, 188-195.	1.0	2
851	Integration of OV6 expression and CD68+ tumor-associated macrophages with clinical features better predicts the prognosis of patients with hepatocellular carcinoma. <i>Translational Oncology</i> , 2022, 25, 101509.	1.7	5
852	What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. <i>JHEP Reports</i> , 2022, 4, 100578.	2.6	9
853	The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	15
854	Re-evaluation of the anticarcinogenic effect of metformin in a chemically-induced hepatocellular carcinoma model not associated with diabetes. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2022, 9, 560-576.	0.2	0
855	Association of Concurrent Metabolic Syndrome with Long-term Oncological Prognosis Following Liver Resection for Hepatocellular Carcinoma Among Patients with Chronic Hepatitis B Virus Infection: A Multicenter Study of 1753 Patients. <i>Annals of Surgical Oncology</i> , 2023, 30, 346-358.	0.7	7

#	ARTICLE	IF	CITATIONS
856	Radiomics-based nomogram as predictive model for prognosis of hepatocellular carcinoma with portal vein tumor thrombosis receiving radiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
857	Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11188.	1.8	0
858	The Role of Sex in Acute and Chronic Liver Damage. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10654.	1.8	12
859	Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status. <i>Hepatology International</i> , 2022, 16, 1282-1296.	1.9	8
860	TRIM proteins in hepatocellular carcinoma. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	13
861	Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 2039-2050.	1.4	3
862	Multimomics analyses and machine learning of nuclear receptor coactivator 6 reveal its essential role in hepatocellular carcinoma. <i>Cancer Science</i> , 2023, 114, 75-90.	1.7	2
863	Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2023, 164, 72-88.e18.	0.6	48
864	Long non-coding RNA LINC00992 promotes hepatocellular carcinoma cell proliferation, metastasis, and invasiveness by downregulating MicroRNA miR-361-5p expression to increase levels of the transcription factor twist1. <i>Pathology Research and Practice</i> , 2022, 238, 154115.	1.0	3
865	pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors. <i>Journal of Controlled Release</i> , 2022, 350, 525-537.	4.8	18
866	Functional roles of lncRNA-TUG1 in hepatocellular carcinoma. <i>Life Sciences</i> , 2022, 308, 120974.	2.0	15
867	The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook. <i>Molecular Immunology</i> , 2022, 151, 218-230.	1.0	7
868	Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2022, 112, 109223.	1.7	7
869	Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity. <i>Cancer Letters</i> , 2022, 548, 215898.	3.2	5
870	HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2022, 32, 101352.	0.7	2
871	Coffee: Health effects and various disease treatments. <i>Food and Health</i> , 2022, 8, 344-358.	0.2	1
872	A well-matched marriage of immunotherapy and radiofrequency ablation to reduce the relapse and progression of hepatocellular carcinoma. <i>BioScience Trends</i> , 2022, 16, 377-380.	1.1	2
873	Circular RNA hsa_circ_0005218 Promotes the Early Recurrence of Hepatocellular Carcinoma by Targeting the miR-31-5p/CDK1 Pathway. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
874	Nonalcoholic steatohepatitis-induced hepatocellular carcinoma. , 2022, 7, 1.	0.1	0
875	Locoregional Therapies for Hepatocellular Carcinoma. , 2022, , 307-324.		0
876	Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy. Nanoscale Advances, 2022, 4, 4847-4862.	2.2	2
877	Construction and Evaluation of GPC3-Targeted Immunotoxins as a Novel Therapeutic Modality for Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
878	The value of thioredoxin level and its gene Polymorphism in diagnosis of post- HCV Hepatocellular Carcinoma. Current Cancer Therapy Reviews, 2022, 18, .	0.2	0
879	Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers, 2022, 14, 4142.	1.7	3
880	Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma. Cancer Medicine, 2023, 12, 3237-3259.	1.3	3
881	Clinicopathological Implications of ASAP1 Expression in Hepatocellular Carcinoma. Pathology and Oncology Research, 0, 28, .	0.9	3
882	A Web-Based Prediction Model for Estimating the Probability of Post-hepatectomy Major Complications in Patients with Hepatocellular Carcinoma: A Multicenter Study from a Hepatitis B Virus-Endemic Area. Journal of Gastrointestinal Surgery, 2022, 26, 2082-2092.	0.9	1
883	Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. Liver Cancer, 2023, 12, 116-128.	4.2	5
884	Cancer suppression by ferroptosis and its role in digestive system tumors. World Chinese Journal of Digestology, 2022, 30, 718-728.	0.0	0
885	HCC or Something Else? Frequency of Various Benign and Malignant Etiologies in Cirrhotic Patients with Newly Detected Focal Liver Lesions in Relation to Different Clinical and Sonographic Parameters. Diagnostics, 2022, 12, 2079.	1.3	3
886	Farnesiferol C Exerts Antiproliferative Effects on Hepatocellular Carcinoma HepG2 Cells by Instigating ROS-Dependent Apoptotic Pathway. Pharmaceuticals, 2022, 15, 1070.	1.7	5
887	Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma. Cells, 2022, 11, 2654.	1.8	2
888	A Genomic Instability-Related Long Noncoding RNA Signature for Predicting Hepatocellular Carcinoma Prognosis. Journal of Oncology, 2022, 2022, 1-17.	0.6	2
889	The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?. Molecules, 2022, 27, 5292.	1.7	7
890	Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma. Oncologist, 0, , .	1.9	2
891	The Role of miR-29s in Human Cancers€”An Update. Biomedicines, 2022, 10, 2121.	1.4	5

#	ARTICLE	IF	CITATIONS
892	Establishment of Nomogram Model for Minimally Invasive Treatment of Small Hepatocellular Carcinoma Based on CD8+T Cell Counts. <i>OncoTargets and Therapy</i> , 0, Volume 15, 925-940.	1.0	0
893	STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 99-119.	2.3	5
894	TRIM36 inhibits tumorigenesis through the Wnt/ β -catenin pathway and promotes caspase-dependent apoptosis in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, .	1.8	2
895	Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
896	PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
897	Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
898	Sorafenib-Loaded Cu ₂ xSe Nanoparticles Boost Photothermal Synergistic Targeted Therapy against Hepatocellular Carcinoma. <i>Nanomaterials</i> , 2022, 12, 3191.	1.9	6
899	Diagnosis of hepatocellular carcinoma based on salivary protein glycopatterns and machine learning algorithms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1963-1973.	1.4	6
901	Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. <i>Hepatology</i> , 2023, 77, 1150-1163.	3.6	41
902	Elucidating the mechanism behind and investigating the efficacy of Traditional Chinese Medicine and Traditional Tibetan Medicine in combination with standard therapeutics in hepatocellular carcinoma and cholangiocarcinoma in vitro. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
903	The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
904	MicroRNA-mediated regulation of key signaling pathways in hepatocellular carcinoma: A mechanistic insight. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	14
905	Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
906	A necroptosis-related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
907	Synergizing liver systemic treatments with interventional oncology: friend or foe?. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	1
908	Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression. <i>Biomedicines</i> , 2022, 10, 2344.	1.4	3
910	Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
911	Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma. <i>Biomedicines</i> , 2022, 10, 2277.	1.4	1

#	ARTICLE	IF	CITATIONS
912	Risk prediction model for early postoperative death in patients with hepatocellular carcinoma: a retrospective study based on random forest algorithm and logistic regression. <i>European Journal of Gastroenterology and Hepatology</i> , 0, Publish Ahead of Print, .	0.8	1
913	Induction of ROS mediated genomic instability, apoptosis and G0/G1 cell cycle arrest by erbium oxide nanoparticles in human hepatic Hep-G2 cancer cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
914	Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
915	A Novel Online Calculator to Predict Risk of Microvascular Invasion in the Preoperative Setting for Hepatocellular Carcinoma Patients Undergoing Curative-Intent Surgery. <i>Annals of Surgical Oncology</i> , 2023, 30, 725-733.	0.7	11
916	The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
917	Effect of Biliary Tract Invasion with Obstructive Jaundice on the Prognosis of Patients With Unresectable Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2023, 30, 483-491.	1.3	1
918	Nucleic acids and proteins carried by exosomes from various sources: Potential role in liver diseases. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	1
919	Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
920	Inferring causal gene regulatory network via GreyNet: From dynamic grey association to causation. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
921	HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway. <i>Annals of Hepatology</i> , 2022, , 100759.	0.6	0
922	Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. <i>Cancer Cell</i> , 2022, 40, 986-998.e5.	7.7	28
923	Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
924	Identification and Validation of an Inflammatory Response-Related Polygenic Risk Score as a Prognostic Marker in Hepatocellular Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-14.	0.6	1
926	A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
927	Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	10
929	The role of RNA modification in hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
930	PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. <i>Biomolecules</i> , 2022, 12, 1226.	1.8	4
931	Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. <i>Hepatology</i> , 2023, 77, 1943-1957.	3.6	5

#	ARTICLE	IF	CITATIONS
933	Evaluation of the Hepatocellular Carcinoma Predictive Scores PAGE-B and mPAGE-B among Brazilian Patients with Chronic Hepatitis B Virus Infection. <i>Viruses</i> , 2022, 14, 1968.	1.5	2
934	Development and validation of a modified albuminâ€“bilirubin grade and Î±-fetoprotein score (mALF) Tj ETQq1 1 0.784314 rgBT /Over International, 2023, 17, 86-96.	1.9	7
935	Drastic sex-dependent etiological distribution in severe liver diseases from Gabon. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
936	Molecular Classification of Hepatocellular Carcinoma Using Wntâ€“Hippo Signaling Pathway-Related Genes. <i>Cancers</i> , 2022, 14, 4580.	1.7	3
937	Activation of the Î²â€“TrCP/Î²BÎ±/inflammation axis limits the sensitivity of liver cancer cells to neddylation inhibition. <i>Oncology Reports</i> , 2022, 48, .	1.2	1
938	Serum steroid profiling of hepatocellular carcinoma associated with hyperadrenocorticism in dogs: A preliminary study. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	3
939	A proposal for T1 subclassification in hepatocellular carcinoma: reappraisal of the AJCC 8th edition. <i>Hepatology International</i> , 2022, 16, 1353-1367.	1.9	4
940	Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
941	Berberine enhances the anti-hepatocellular carcinoma effect of NK92-M1 cells through inhibiting IFN-gamma-mediated PD-L1 expression. <i>Liver Research</i> , 2022, 6, 167-174.	0.5	0
942	Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. <i>Cancers</i> , 2022, 14, 4647.	1.7	1
943	Risk of HCC in Patients with HBV, Role of Antiviral Treatment. <i>Current Hepatology Reports</i> , 2022, 21, 76-86.	0.4	2
944	A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13041-13051.	2.9	27
945	Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 28, 5250-5264.	1.4	8
946	NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 513-520.	3.2	30
947	Circular RNA hsa_circ_0062682 Binds to YBX1 and Promotes Oncogenesis in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4524.	1.7	5
948	Cancer stemness-associated LINC02475 serves as a novel biomarker for diagnosis and prognosis prediction of hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
949	A <sc>CD8</sc> ⁺ T cellâ€“related genes prognostic model for hepatocellular carcinoma patients. <i>Scandinavian Journal of Immunology</i> , 0, , .	1.3	1
950	The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8

#	ARTICLE	IF	CITATIONS
951	Integrative Analysis Reveals the Potential Role and Prognostic Value of GOLM1 in Hepatocellular Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-24.	1.9	1
952	Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11363.	1.8	6
953	Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
954	Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States. <i>Hepatology Communications</i> , 2022, 6, 3443-3456.	2.0	5
956	Apigenin Promotes TNF α -Induced Apoptosis, Necroptosis, G2/M Phase Cell Cycle Arrest, and ROS Generation through Inhibition of NF- κ B Pathway in Hep3B Liver Cancer Cells. <i>Cells</i> , 2022, 11, 2734.	1.8	16
957	OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
958	Gene mining of immune microenvironment in hepatocellular carcinoma. <i>Medicine (United States)</i> , 2022, 101, e30453.	0.4	3
959	Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
960	Liver organoids: an in vitro 3D model for liver cancer study. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	13
961	Development of novel 9-O-substituted-13-octylberberine derivatives as potential anti-hepatocellular carcinoma agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 2423-2433.	2.5	2
963	Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
964	LINC00467: an oncogenic long noncoding RNA. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1
965	The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	1
966	Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. <i>Oncolimmunology</i> , 2022, 11, .	2.1	1
967	Pseudogene UBE2MP1 derived transcript enhances in vitro cell proliferation and apoptosis resistance of hepatocellular carcinoma cells through miR-145-5p/RGS3 axis. <i>Aging</i> , 2022, 14, 7906-7925.	1.4	5
968	A Macrophage Differentiation-Mediated Gene: DDX20 as a Molecular Biomarker Encompassing the Tumor Microenvironment, Disease Staging, and Prognoses in Hepatocellular Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-22.	1.9	2
969	Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
970	Liver cancer metabolism: a hexokinase from the stars. <i>Nature Metabolism</i> , 2022, 4, 1225-1226.	5.1	3

#	ARTICLE	IF	CITATIONS
971	Unrecognized liver cirrhosis is common and associated with worse survival in hepatocellular carcinoma: A nationwide cohort study of 3473 patients. <i>Journal of Internal Medicine</i> , 2023, 293, 184-199.	2.7	3
972	Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers. <i>International Journal of Cancer</i> , 2023, 152, 1107-1114.	2.3	6
973	The pathogenesis of liver cancer and the therapeutic potential of bioactive substances. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
974	Recurrence of Early Hepatocellular Carcinoma after Surgery May Be Related to Intestinal Oxidative Stress and the Development of a Predictive Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	1.9	1
975	lncRNA PVT1: a novel oncogene in multiple cancers. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	15
976	Application of genomic selection and experimental techniques to predict cell death and immunotherapeutic efficacy of ferroptosis-related CXCL2 in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
977	TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2023, 127, 374-384.	0.8	6
978	Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. <i>Liver Cancer</i> , 2023, 12, 72-84.	4.2	16
979	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. <i>ESMO Open</i> , 2022, 7, 100591.	2.0	47
980	Bioinformatics Analysis of NAP1L1 in Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2022, 12, 9325-9336.	0.0	0
981	In Vivo, Ex Vivo, and In Vitro Models Systems for Liver Cancer Research. , 2022, , 1-21.		0
982	Organ Systems. , 2022, , 225-413.		0
983	Recent research progress in galactose-based fluorescent probes for detection of biomarkers of liver diseases. <i>Chemical Communications</i> , 2022, 58, 12518-12527.	2.2	6
984	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
985	The SNHG1-Centered ceRNA Network Regulates Cell Cycle and Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 258, 265-276.	0.5	17
986	Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. , 2022, , 125-200.		0
987	The Complement System: A Potential Therapeutic Target in Liver Cancer. <i>Life</i> , 2022, 12, 1532.	1.1	1
988	Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11623.	1.8	0

#	ARTICLE	IF	CITATIONS
989	Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity. <i>Cancer Discovery</i> , 2023, 13, 432-453.	7.7	46
990	Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. <i>World Journal of Hepatology</i> , 0, 14, 1862-1874.	0.8	5
991	Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12327.	1.8	14
992	Asymptomatic Hepatocellular Carcinoma (Clinical Case). <i>Kreativna Ć Hirurģi Ć I Onkologi Ć</i> , 2022, 12, 256-260.	0.1	1
993	Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. <i>Pharmaceutics</i> , 2022, 14, 2263.	2.0	3
994	Stereotactic body radiation therapy versus radiofrequency ablation in hepatocellular carcinoma: an up-date meta-analysis. <i>Abdominal Radiology</i> , 0, , .	1.0	0
995	MiR-23b-3p suppresses epithelial-mesenchymal transition, migration, and invasion of hepatocellular carcinoma cells by targeting c-MET. <i>Heliyon</i> , 2022, 8, e11135.	1.4	2
996	Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?. <i>Livers</i> , 2022, 2, 315-335.	0.8	1
997	Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. <i>Hpb</i> , 2023, 25, 218-228.	0.1	3
998	Cellular, Molecular and Proteomic Characteristics of Early Hepatocellular Carcinoma. <i>Current Issues in Molecular Biology</i> , 2022, 44, 4714-4734.	1.0	3
999	Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2- <i>b</i>]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 14809-14831.	2.9	5
1000	Cytotoxic T Cell Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) in Viral Hepatitis C-Mediated Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12541.	1.8	7
1001	Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. <i>Journal of Personalized Medicine</i> , 2022, 12, 1788.	1.1	9
1002	Autoantibody against Tumor-Associated Antigens as Diagnostic Biomarkers in Hispanic Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2022, 11, 3227.	1.8	2
1003	Ideal patients for liver resection in Barcelona Clinic Liver Cancer or Hong Kong Liver clinic systems for hepatocellular carcinoma: Conservative or aggressive?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1004	NSUN5 promotes progression and predicts poor prognosis in hepatocellular carcinoma. <i>Oncology Letters</i> , 2022, 24, .	0.8	5
1005	Nomogram Estimating Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma From Preoperative Gadoxetate Disodium-Enhanced <i>sc</i> p>MRI</sc>. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 1893-1905.	1.9	11
1006	Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	7

#	ARTICLE	IF	CITATIONS
1008	Identification and analysis of DNA methylation-driven signatures for prognostic and immune microenvironments evaluation in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1009	m7C regulator-mediated methylation modification patterns define immune cell infiltration and patient survival. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1010	Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy. <i>Cancers</i> , 2022, 14, 5292.	1.7	3
1012	Upregulation of Superenhancer-Driven LncRNA FASRL by USF1 Promotes De Novo Fatty Acid Biosynthesis to Exacerbate Hepatocellular Carcinoma. <i>Advanced Science</i> , 2023, 10, .	5.6	12
1013	Identifying tumor immunity-associated molecular features in liver hepatocellular carcinoma by multi-omics analysis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	3
1014	Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial. <i>Hepatology International</i> , 2022, 16, 1368-1378.	1.9	7
1015	Role of gasdermin family proteins in the occurrence and progression of hepatocellular carcinoma. <i>Heliyon</i> , 2022, 8, e11035.	1.4	3
1016	Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response. <i>Cancers</i> , 2022, 14, 4850.	1.7	0
1017	Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5013.	1.7	12
1019	Combined clinical features and MRI parameters for the prediction of VEGFR2 in hepatocellular carcinoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1020	Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence. <i>Cancers</i> , 2022, 14, 5114.	1.7	12
1021	VEZF1, destabilized by STUB1, affects cellular growth and metastasis of hepatocellular carcinoma by transcriptionally regulating PAQR4. <i>Cancer Gene Therapy</i> , 2023, 30, 256-266.	2.2	2
1022	Association of chronic kidney disease with total and site-specific cancer incidence in participants of the Japan Public Health Center-based Prospective Study. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.4	2
1023	Adeno-associated virus infection and its impact in human health: an overview. <i>Virology Journal</i> , 2022, 19, .	1.4	9
1025	Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case-control study. <i>Liver International</i> , 2023, 43, 221-233.	1.9	18
1026	Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. <i>Advanced Science</i> , 2022, 9, .	5.6	7
1027	The evolution of anatomical hepatectomy: Past, present, and future. , 2022, 1, 199-204.		1
1028	Effect of Autotransfusion in HCC Surgery on Survival and Recurrence: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 4837.	1.7	4

#	ARTICLE	IF	CITATIONS
1029	An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
1030	Non-Coding RNA Related to MAPK Signaling Pathway in Liver Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11908.	1.8	7
1031	Metabolic profile predicts incident cancer: A large-scale population study in the UK Biobank. <i>Metabolism: Clinical and Experimental</i> , 2023, 138, 155342.	1.5	4
1032	Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. <i>Cancer Medicine</i> , 2023, 12, 5436-5449.	1.3	3
1033	Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1034	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1036	Diagnostic performance of dual-energy computed tomography for HCC after transarterial chemoembolization: Utility of virtual unenhanced and low keV virtual monochromatic images. <i>Medicine (United States)</i> , 2022, 101, e31171.	0.4	0
1037	Is Fasting Good When One Is at Risk of Liver Cancer?. <i>Cancers</i> , 2022, 14, 5084.	1.7	4
1039	The interplay of transcriptional coregulator NUPR1 with SREBP1 promotes hepatocellular carcinoma progression via upregulation of lipogenesis. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	3
1040	One-step fabrication of lidocaine/CalliSpheres® composites for painless transcatheter arterial embolization. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
1041	Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, 22, 7-13.	0.6	8
1042	Expression profile and prognostic values of SMC family members in HCC. <i>Medicine (United States)</i> , 2022, 101, e31336.	0.4	4
1043	Evoking and enhancing ferroptosis of cancer stem cells by a liver-targeted and metal-organic framework-based drug delivery system inhibits the growth and lung metastasis of hepatocellular carcinoma. <i>Chemical Engineering Journal</i> , 2023, 454, 140044.	6.6	5
1044	LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	8
1045	Comparison of survival and post-operation outcomes for minimally invasive versus open hepatectomy in hepatocellular carcinoma: A systematic review and meta-analysis of case-matched studies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1046	Endoplasmic Reticulum Stress and Metabolism in Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2023, 193, 1377-1388.	1.9	6
1047	Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment. <i>Journal of Hepatology</i> , 2023, 78, 343-355.	1.8	10
1048	A signature based on <sc>NKG2D</sc> ligands to predict the recurrence of hepatocellular carcinoma after radical resection. <i>Cancer Medicine</i> , 0, , .	1.3	1

#	ARTICLE	IF	CITATIONS
1049	Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1050	Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 6498.	1.0	7
1051	Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1052	Liver Fibrosis, Liver Cancer, and Advances in Therapeutic Approaches. <i>Livers</i> , 2022, 2, 372-386.	0.8	1
1053	Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
1054	NPRL2 downregulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. <i>Hepatology Communications</i> , 2022, 6, 3563-3577.	2.0	3
1055	Comprehensive analysis of the expression and prognosis for IQ motif-containing GTPase-activating proteins in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
1056	The role of radiation therapy in the treatment of spine metastases from hepatocellular carcinoma: a systematic review and meta-analysis. <i>Neurosurgical Focus</i> , 2022, 53, E12.	1.0	4
1057	IFN γ -IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. <i>Cancer Letters</i> , 2023, 552, 215977.	3.2	9
1058	Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma. <i>Advances in Biological Regulation</i> , 2023, 87, 100925.	1.4	0
1059	Regularized Ultrasound Phantom-Free Local Attenuation Coefficient Slope (ACS) Imaging in Homogeneous and Heterogeneous Tissues. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2022, 69, 3338-3352.	1.7	4
1060	The Research Progress of LncRNA MAPKAPK5-AS1 in Malignant Tumors and Other Diseases. <i>Advances in Clinical Medicine</i> , 2022, 12, 10241-10248.	0.0	1
1061	Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211348.	0.6	2
1062	Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113962.	2.5	3
1063	From liver fibrosis to hepatocarcinogenesis: Role of excessive liver H ₂ O ₂ and targeting nanotherapeutics. <i>Bioactive Materials</i> , 2023, 23, 187-205.	8.6	5
1064	Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment. <i>Biomedicines</i> , 2022, 10, 2824.	1.4	1
1065	Circular RNA hsa_circ_0051040 Promotes Hepatocellular Carcinoma Progression by Sponging miR-569 and Regulating ITGAV Expression. <i>Cells</i> , 2022, 11, 3571.	1.8	3
1066	Advances in Targeted Immunotherapy for Hepatobiliary Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13961.	1.8	10

#	ARTICLE	IF	CITATIONS
1067	Laparoscopic electrochemotherapy for the treatment of hepatocellular carcinoma: Technological advancement. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1068	Transcriptional regulation of <scp>NDUFA4L2</scp> by <scp>NFIB</scp> induces sorafenib resistance by decreasing reactive oxygen species inÂhepatocellular carcinoma. <i>Cancer Science</i> , 2023, 114, 793-805.	1.7	5
1069	A vector finite element approach to temperature dependent parameters of microwave ablation for liver cancer. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2023, 39, .	1.0	3
1070	Wnt/ β 2-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5468.	1.7	8
1071	Evolving therapeutic landscape of advanced hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 203-222.	8.2	113
1073	Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 767-780.	1.5	1
1074	Computational Modeling of Microwave Tumor Ablation. <i>Bioengineering</i> , 2022, 9, 656.	1.6	3
1075	Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1066-1082.	2.8	5
1076	Constitutively Active Androgen Receptor in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13768.	1.8	8
1077	Elevated neutrophil extracellular traps by HBVâ€mediated S100A9â€TLR4/RAGEâ€ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma. <i>Cancer Communications</i> , 2023, 43, 225-245.	3.7	28
1078	Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1079	Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: A systematic review and meta-analysis of propensity score-matched studies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1080	Multifunctional Drug-Loaded Phase-Change Nanoparticles Inhibit the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Affecting the Activity of Activated Hepatic Stellate Cells. <i>BioMed Research International</i> , 2022, 2022, 1-18.	0.9	1
1081	Is liver regeneration key in hepatocellular carcinoma development?. <i>Trends in Cancer</i> , 2023, 9, 140-157.	3.8	4
1082	IL-32 and IL-34 in hepatocellular carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1083	Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2022, 15, 1368.	1.7	5
1084	RHO GTPase family in hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	13
1085	Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. <i>Liver Cancer International</i> , 2023, 4, 13-27.	0.2	0

#	ARTICLE	IF	CITATIONS
1086	Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e31479.	0.4	2
1087	Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1088	High Expression of POGK Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 8650-8667.	0.9	2
1089	N ⁶ -methyladenosine-modified lncRNA ARHGAP5-AS1 stabilises CSDE1 and coordinates oncogenic RNA regulons in hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	19
1092	Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	1
1093	Diagnostic implication of a circulating serum-based three-microRNA signature in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
1094	Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13834.	1.8	9
1095	Identification of Hypoxia-Related Prognostic Signature and Competing Endogenous RNA Regulatory Axes in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13590.	1.8	7
1096	Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	1
1097	Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
1098	Integrative multiomics evaluation reveals the importance of pseudouridine synthases in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	12
1099	Pediatric hepatocellular carcinoma associated with Niemann-Pick disease type C: Case report and literature review. <i>JIMD Reports</i> , 2023, 64, 27-34.	0.7	1
1100	Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein. <i>Oncogenesis</i> , 2022, 11, .	2.1	8
1101	LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1102	Rapid progression of hepatocellular carcinoma in a pregnant woman: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	0
1103	Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2022, 113, 109411.	1.7	0
1104	SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway. <i>Biochemical and Biophysical Research Communications</i> , 2022, 637, 161-169.	1.0	4
1105	Barhi date (<i>Phoenix dactylifera</i>) extract ameliorates hepatocellular carcinoma in male rats. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113976.	2.5	2

#	ARTICLE	IF	CITATIONS
1106	Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2022, 113, 109393.	1.7	2
1107	Polymeric nanomedicines for the treatment of hepatic diseases. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	10
1108	Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1109	Exploring the mechanisms underlying the therapeutic effect of the Radix Bupleuri-Rhizoma Cyperi herb pair on hepatocellular carcinoma using multilevel data integration and molecular docking. <i>Aging</i> , 2022, 14, 9103-9127.	1.4	1
1110	Optimizing Survival for Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Report and Current Perspectives. <i>Transplantation Proceedings</i> , 2022, 54, 2593-2597.	0.3	1
1111	Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2022, 18, 3769-3782.	1.1	11
1112	Hematological and neurological expressed 1 (HN1) activates c-Myc signaling by inhibiting ubiquitin-mediated proteasomal degradation of c-Myc in hepatocellular carcinoma. <i>Cell Biology International</i> , 2023, 47, 560-572.	1.4	5
1113	Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis. <i>International Immunopharmacology</i> , 2023, 114, 109519.	1.7	2
1114	Blood Supply and Oxygenation Status of the Liver: From Physiology to Malignancy. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 263-267.	0.8	0
1115	Construction of pH-responsive polydopamine coated magnetic layered hydroxide nanostructure for intracellular drug delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2023, 182, 12-20.	2.0	11
1116	Learning curve of microwave ablation for liver cancers. <i>European Journal of Radiology</i> , 2023, 158, 110613.	1.2	1
1117	Long noncoding RNA HAND2-AS1: A crucial regulator of malignancy. <i>Clinica Chimica Acta</i> , 2023, 539, 162-169.	0.5	2
1118	Diagnostic potential of site-specific serotransferrin N-glycosylation in discriminating different liver diseases. <i>Clinica Chimica Acta</i> , 2023, 539, 175-183.	0.5	1
1119	Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma. <i>Computers in Biology and Medicine</i> , 2023, 152, 106348.	3.9	1
1120	Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188841.	3.3	0
1121	Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2023, 27, 101600.	1.7	3
1122	Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2023, 640, 173-182.	1.0	3
1123	Vitamin D ameliorates diethylnitrosamine-induced liver preneoplasia: A pivotal role of CYP3A4/CYP2E1 via DPP-4 enzyme inhibition. <i>Toxicology and Applied Pharmacology</i> , 2023, 458, 116324.	1.3	1

#	ARTICLE	IF	CITATIONS
1124	Zymolytic grain extract facilitates the conversion of liver tumor cells to hepatocyte-like cells through hepatocyte nuclear factors. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114029.	2.5	0
1125	Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188848.	3.3	3
1126	Diagnosis of hepatocellular carcinoma using deep network with multi-view enhanced patterns mined in contrast-enhanced ultrasound data. <i>Engineering Applications of Artificial Intelligence</i> , 2023, 118, 105635.	4.3	4
1127	Hepatoma-targeting and reactive oxygen species-responsive chitosan-based polymeric micelles for delivery of celastrol. <i>Carbohydrate Polymers</i> , 2023, 303, 120439.	5.1	7
1128	The role of circadian gene timeless in gastrointestinal cancers. <i>Gene Reports</i> , 2023, 30, 101722.	0.4	0
1129	An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET+ hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2023, 33, 101412.	0.7	3
1130	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211173.	0.8	2
1131	Interdisciplinary Approach in Hepatobiliary Cancers. , 2022, , 1-40.		0
1132	Prediction of Immune and Stromal Cell Population Abundance from Hepatocellular Carcinoma Whole Slide Images Using Weakly Supervised Learning. <i>Lecture Notes in Computer Science</i> , 2022, , 143-153.	1.0	0
1133	Delivery of Adriamycin Loaded Niosomes for Liver Cancer Treatment. <i>Journal of Biomedical Nanotechnology</i> , 2022, 18, 1763-1769.	0.5	0
1134	Aspergillumarin A Inhibits Cell Proliferation by Inducing G ₀ /G ₁ Phase Arrest in HepG2 Hepatocellular Carcinoma Cells. <i>Science of Advanced Materials</i> , 2022, 14, 1185-1189.	0.1	0
1135	The value of quantitative MR elastography-based stiffness for assessing the microvascular invasion grade in hepatocellular carcinoma. <i>European Radiology</i> , 2023, 33, 4103-4114.	2.3	4
1136	miR-9 and miR-181a Target Gab2 to Inhibit the Proliferation and Migration of Hepatocellular Carcinoma HepG2 Cells. <i>Genes</i> , 2022, 13, 2152.	1.0	0
1137	Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1138	Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1217-1228.	1.8	7
1139	Hepatocellular carcinoma risk-stratification based on ASGR1 in circulating epithelial cells for cancer interception. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	5
1140	Integrated Analysis of Altered lncRNA, circRNA, microRNA, and mRNA Expression in Hepatocellular Carcinoma Carrying TERT Promoter Mutations. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1201-1215.	1.8	1
1141	Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. <i>Gut</i> , 2023, 72, 1568-1580.	6.1	6

#	ARTICLE	IF	CITATIONS
1142	Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	7
1143	Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases. <i>Journal of Clinical Medicine</i> , 2022, 11, 6901.	1.0	0
1144	Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1145	The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1146	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1151-1167.	1.9	3
1147	Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1148	Total flavonoids of <i>Oldenlandia diffusa</i> (Willd.) Roxb. suppresses the growth of hepatocellular carcinoma through endoplasmic reticulum stress-mediated autophagy and apoptosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1149	Healthcare Costs for Medicare Patients With Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2327-2337.e9.	2.4	3
1150	Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
1151	Clinical value of identifying genes that inhibit hepatocellular carcinomas. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 1009-1035.	1.5	1
1152	An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments. <i>BioMed Research International</i> , 2022, 2022, 1-8.	0.9	3
1153	Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam. <i>Viruses</i> , 2022, 14, 2571.	1.5	0
1154	Gender Dimorphism in Hepatic Carcinogenesis-Related Gene Expression Associated with Obesity as a Low-Grade Chronic Inflammatory Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15002.	1.8	1
1155	Special presentation of bronchobiliary fistula after transcatheter arterial chemoembolization: A case report. <i>Medicine (United States)</i> , 2022, 101, e31596.	0.4	3
1156	Sex difference in the associations among risk factors with hepatitis B and C infections in a large Taiwanese population study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1157	Ferritin Nanocaged Doxorubicin Potentiates Chemo-immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death. <i>Small Methods</i> , 2023, 7, .	4.6	10
1158	DN200434, an orally available inverse agonist of estrogen-related receptor β , induces ferroptosis in sorafenib-resistant hepatocellular carcinoma. <i>BMB Reports</i> , 2022, 55, 547-552.	1.1	8
1159	Highlighting novel targets in immunotherapy for liver cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 1029-1041.	1.4	3

#	ARTICLE	IF	CITATIONS
1160	ARFIP2 Regulates EMT and Autophagy in Hepatocellular Carcinoma in Part Through the PI3K/Akt Signalling Pathway. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1323-1339.	1.8	4
1161	Circadian gene CSNK1D promoted the progression of hepatocellular carcinoma by activating Wnt/ β -catenin pathway via stabilizing Dishevelled Segment Polarity Protein 3. <i>Biological Procedures Online</i> , 2022, 24, .	1.4	5
1162	Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 73-83.	1.4	3
1163	Role of follistatin-like protein 1 in liver diseases. <i>Experimental Biology and Medicine</i> , 2023, 248, 193-200.	1.1	2
1164	The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. <i>Future Oncology</i> , 2022, 18, 4119-4136.	1.1	4
1165	Combining α -GT, PIVKA II , and AFP to Predict Long-Term Prognosis in Patients with Hepatocellular Carcinoma after Hepatectomy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 0, , .	0.9	0
1166	Dissecting intratumor heterogeneity in HCC: new research strategies and clinical implications. <i>Carcinogenesis</i> , 2022, 43, 1103-1109.	1.3	2
1167	Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 28, 6433-6477.	1.4	7
1168	Clinical Significance of TUBGCP4 Expression in Hepatocellular Carcinoma. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-7.	0.7	1
1169	Glycosylation-related molecular subtypes and risk score of hepatocellular carcinoma: Novel insights to clinical decision-making. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
1170	Generation of multicellular tumor spheroids with micro-well array for anticancer drug combination screening based on a valuable biomarker of hepatocellular carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	4
1171	Upregulated UBE4B expression correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	0
1172	Circulating Metabolic Markers Related to the Diagnosis of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	1
1173	Reprogramming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2022, 113, 109475.	1.7	3
1174	Impact of type 2 diabetes mellitus on the prognosis of patients with hepatocellular carcinoma after laparoscopic liver resection: A multicenter retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1175	A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
1176	Prognostic factors for disease-free survival in postoperative patients with hepatocellular carcinoma and construction of a nomogram model. <i>World Journal of Clinical Cases</i> , 0, 10, 13250-13263.	0.3	0
1177	Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10

#	ARTICLE	IF	CITATIONS
1178	Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy. <i>BioFactors</i> , 2023, 49, 405-414.	2.6	7
1179	Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1180	Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology. <i>Medicina (Lithuania)</i> , 2022, 58, 1803.	0.8	0
1181	Genetic Variation of SAMM50 Is Not an Independent Risk Factor for Alcoholic Hepatocellular Carcinoma in Caucasian Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15353.	1.8	2
1182	Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1183	The role of Neanderthal introgression in liver cancer. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	1
1185	Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma. <i>Cellular Signalling</i> , 2023, 104, 110565.	1.7	2
1186	Advanced Hepatocellular Carcinoma in Adults Without Cirrhosis: A Single-Institution Retrospective Review. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1299-1307.	1.8	0
1187	Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, 22, 34-40.	0.6	2
1188	Immunological classification of hepatitis B virus-positive hepatocellular carcinoma by transcriptome analysis. <i>World Journal of Hepatology</i> , 0, 14, 1997-2011.	0.8	0
1189	Inflammation and Fibrosis in Patients with Non-Cirrhotic Hepatitis B Virus-Associated Hepatocellular Carcinoma: Impact on Prognosis after Hepatectomy and Mechanisms Involved. <i>Current Oncology</i> , 2023, 30, 196-218.	0.9	2
1190	PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. <i>Cells</i> , 2022, 11, 4132.	1.8	5
1192	The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers: a review. <i>Oncogene</i> , 2023, 42, 549-558.	2.6	2
1193	A review of current evidence about lncRNA MEC3: A tumor suppressor in multiple cancers. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	16
1194	Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5997.	1.7	7
1195	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 206-216.	4.5	19
1196	Kinetic parameter estimation of hepatocellular carcinoma on ^{18}F -FDG PET/CT based on Bayesian method. <i>Medical Physics</i> , 2023, 50, 2860-2871.	1.6	1
1197	Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer. <i>Genome Medicine</i> , 2022, 14, .	3.6	10

#	ARTICLE	IF	CITATIONS
1198	Pathogenesis to management of hepatocellular carcinoma. <i>Genes and Cancer</i> , 2022, 13, 72-87.	0.6	2
1199	Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1247-1261.	1.8	7
1200	The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. <i>Cancers</i> , 2022, 14, 6151.	1.7	3
1201	Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	10
1202	Obeticholic acid and 5 β -cholanolic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1203	Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma. <i>Molecular Therapy</i> , 2023, 31, 1756-1774.	3.7	3
1204	Comparative Study between the 3D Liver Spheroid Models Developed from HepG2 and Immortalized Hepatocyte-Like Cells with Primary Hepatic Stellate Coculture for Drug Metabolism Analysis and Anticancer Drug Screening. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	2
1205	Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1206	Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1207	The efficacy and safety of a shortened duration of antimicrobial therapy for group A <i>Streptococcus</i> bacteremia. <i>International Journal of Infectious Diseases</i> , 2023, 128, 11-19.	1.5	4
1208	CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2023, 5, 100645.	2.6	3
1209	The treatment of hepatocellular carcinoma with SP94 modified asymmetrical bilayer lipid-encapsulated Cu(DDC) ₂ nanoparticles facilitating Cu accumulation in the tumor. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 145-158.	2.4	3
1210	Integrated genomic analyses of hepatocellular carcinoma. <i>Hepatology International</i> , 0, , .	1.9	6
1211	Multicomponent microspheres with spatiotemporal drug release for post-surgical liver cancer treatment and liver regeneration. <i>Chemical Engineering Journal</i> , 2023, 455, 140585.	6.6	6
1212	Pseudogene SNRFPF1 derived long non-coding RNA facilitates hepatocellular carcinoma progress in vitro by sponging tumor-suppressive miR-126-5p. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1213	CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. <i>Gastroenterology & Hepatology (English Edition)</i> , 2022, 45, 742-752.	0.0	0
1214	Liver resection versus radiofrequency ablation in octogenarian patients for hepatocellular carcinoma: a propensity score multicenter analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 0, , .	1.3	0
1215	Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC: A Proof-of-Concept Study. <i>Cancers</i> , 2022, 14, 6036.	1.7	1

#	ARTICLE	IF	CITATIONS
1216	The Emerging Role of Ferroptosis in Liver Cancers. <i>Life</i> , 2022, 12, 2128.	1.1	7
1217	An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1218	Role of PIVKA-II in screening for malignancies at a hepatobiliary and pancreatic disease center: A large-scale real-world study. , 2022, 1, 209-216.		0
1219	Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Cancers</i> , 2023, 15, 50.	1.7	5
1220	Contrast-Enhanced Ultrasound with Deep Learning with Attention Mechanisms for Predicting Microvascular Invasion in Single Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2023, 30, S73-S80.	1.3	5
1221	Overexpression of KiSS1 Induces the Proliferation of Hepatocarcinoma and Increases Metastatic Potential by Increasing Migratory Ability and Angiogenic Capacity. <i>Molecules and Cells</i> , 2022, 45, 935-949.	1.0	2
1222	A multi-scale, multi-region and attention mechanism-based deep learning framework for prediction of grading in hepatocellular carcinoma. <i>Medical Physics</i> , 2023, 50, 2290-2302.	1.6	4
1223	Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 9813-9825.	0.9	7
1224	CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma. <i>Radiology</i> , 2023, 307, .	3.6	31
1225	Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1279-1298.	1.8	2
1226	Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells. <i>Frontiers in Toxicology</i> , 0, 4, .	1.6	5
1228	Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model. <i>Molecular Pharmaceutics</i> , 0, , .	2.3	4
1229	Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5591-5602.	1.2	12
1230	External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. <i>Clinical and Experimental Medicine</i> , 2023, 23, 1537-1549.	1.9	15
1231	Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1232	A feedback loop between <i>NONHSAT024276</i> and <i>PTBP1</i> inhibits tumor progression and glycolysis in <i>HCC</i> by increasing the <i>PKM1</i> / <i>PKM2</i> ratio. <i>Cancer Science</i> , 2023, 114, 1519-1540.	1.7	3
1233	An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	6
1234	Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population. <i>Molecular Therapy</i> , 2023, 31, 715-728.	3.7	3

#	ARTICLE	IF	CITATIONS
1235	KLF14 regulates the growth of hepatocellular carcinoma cells via its modulation of iron homeostasis through the repression of iron-responsive element-binding protein 2. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	2
1236	Study on Molecular Anti-tumor Mechanism of 2-Thiohydantoin Derivative based on Molecular Docking and Bioinformatic Analyses. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, 440-452.	1.0	2
1238	Development of a Hepatic VX2 carcinoma model in rabbits using an improved minimally invasive method and evaluation with imaging examinations. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 1973.	0.3	1
1239	Liver Cancer: Interdisciplinary Approach. , 2022, , 41-83.		0
1240	Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211406.	0.8	4
1242	Reply to “Biejia-Ruangan compound and incidence of hepatocellular carcinoma”: <i>Journal of Hepatology</i> , 2023, , .	1.8	0
1243	Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	37
1244	Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 433-452.	4.5	14
1245	Curcumin Combats against Gastrointestinal Cancer: A Review of Current Knowledge Regarding Epigenetics Mechanisms with a Focus on DNA Methylation. <i>Current Medicinal Chemistry</i> , 2023, 30, 4374-4388.	1.2	1
1246	Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211480.	1.4	10
1247	Single-cell transcriptome analysis reveals a cancer-associated fibroblast marker gene signature in hepatocellular carcinoma that predicts prognosis. , 2023, 2, 16-25.		1
1248	Preoperative risk score (PreopScore) to predict overall survival after resection for hepatocellular carcinoma. <i>Hpb</i> , 2023, 25, 353-362.	0.1	8
1249	C-Type Lectin Receptors-Triggered Antifungal Immunity May Synergize with and Optimize the Effects of Immunotherapy in Hepatocellular Carcinoma. <i>Journal of Inflammation Research</i> , 0, Volume 16, 19-33.	1.6	0
1250	Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	25
1251	Current status and future perspectives of radiomics in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 43-60.	1.4	7
1252	Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1-16.	1.8	1
1253	TRPM8 promotes hepatocellular carcinoma progression by inducing SNORA55 mediated nuclear-mitochondrial communication. <i>Cancer Gene Therapy</i> , 2023, 30, 738-751.	2.2	2
1254	Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. <i>Cancers</i> , 2023, 15, 533.	1.7	25

#	ARTICLE	IF	CITATIONS
1255	Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma. <i>Medical Review</i> , 2023, .	0.3	0
1256	Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 348.	1.7	3
1257	Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen. <i>Acta Biomaterialia</i> , 2023, 158, 435-448.	4.1	9
1258	Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (â%¥5Âcm): A propensity score matching analysis. <i>Kaohsiung Journal of Medical Sciences</i> , 0, , .	0.8	1
1259	Radiomics: A radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2023, 55, 833-847.	0.4	6
1260	Effect of multi-disciplinary team care program on quality of life, anxiety, and depression in hepatocellular carcinoma patients after surgery: A randomized, controlled study. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
1261	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1262	Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma. <i>PeerJ</i> , 0, 11, e14691.	0.9	1
1263	IL-1Î² neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1264	Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma. <i>Hepatology International</i> , 2023, 17, 112-130.	1.9	8
1265	HCC: RNA-Sequencing in Cirrhosis. <i>Biomolecules</i> , 2023, 13, 141.	1.8	1
1266	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1267	New Approaches to Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2023, 388, 55-69.	13.9	42
1268	Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1269	Engineering orthotopic tumor spheroids with organ-specific vasculatures for local chemoembolization evaluation. <i>Biomaterials Science</i> , 2023, 11, 2115-2128.	2.6	2
1270	A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumabâ€“bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
1271	Systematic analysis of the role and significance of target genes of active ingredients of traditional Chinese medicine injections in the progression and immune microenvironment of hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1272	Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. <i>Current Oncology</i> , 2023, 30, 749-757.	0.9	4

#	ARTICLE	IF	CITATIONS
1273	Cancer Stem Cells are Actually Stem Cells with Disordered Differentiation: the Monophyletic Origin of Cancer. <i>Stem Cell Reviews and Reports</i> , 2023, 19, 827-838.	1.7	4
1274	SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
1275	Hornerâ€™Wadsworthâ€™Emmons reaction as an excellent tool in the synthesis of fluoro-containing biologically important compounds. <i>Organic and Biomolecular Chemistry</i> , 2023, 21, 1095-1120.	1.5	4
1276	Model to predict major complications following liver resection for HCC in patients with metabolic syndrome. <i>Hepatology</i> , 2023, 77, 1527-1539.	3.6	5
1277	Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study. <i>Hepatology International</i> , 0, , .	1.9	0
1278	Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 286-309.	1.4	2
1279	Analysis of the expression and prognostic significance of DDK complex in Hepatocarcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
1280	Polydatin Inhibits Hepatocellular Carcinoma Cell Proliferation and Sensitizes Doxorubicin and Cisplatin through Targeting Cell Mitotic Machinery. <i>Cells</i> , 2023, 12, 222.	1.8	0
1281	Combining Selective Internal Radiation Therapy with Immunotherapy in Treating Hepatocellular Carcinoma and Hepatic Colorectal Metastases: A Systematic Review. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 0, , .	0.7	1
1282	Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 78, 117152.	1.4	2
1283	Revealing Prognostic and Immunotherapy-Sensitive Characteristics of a Novel Cuproptosis-Related LncRNA Model in Hepatocellular Carcinoma Patients by Genomic Analysis. <i>Cancers</i> , 2023, 15, 544.	1.7	0
1285	Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	10
1287	KIF5A upregulation in hepatocellular carcinoma: A novel prognostic biomarker associated with unique tumor microenvironment status. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1288	Short- and Long-Term Outcomes of Indocyanine Green Fluorescence Navigation-Versus Conventional-Laparoscopic Hepatectomy for Hepatocellular Carcinoma: A Propensity Score-Matched, Retrospective, Cohort Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 1991-2002.	0.7	8
1289	KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2023, 222, 113124.	2.5	3
1290	Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2023, 115, 109660.	1.7	4
1291	Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103902.	2.0	1
1292	Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1 α signaling. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114196.	2.5	15

#	ARTICLE	IF	CITATIONS
1293	Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy. <i>Cancer Letters</i> , 2023, 555, 216048.	3.2	12
1294	Imaging Negative Hepatic Lesions: A Rare Case of Infiltrative Hepatocellular Carcinoma Diagnosed With Endoscopic Ultrasound. <i>ACG Case Reports Journal</i> , 2022, 9, e00945.	0.2	0
1295	Linc-ROR drive adriamycin resistance by targeting AP-2 β /Wnt/ β -catenin axis in hepatocellular carcinoma. <i>Cell Biology and Toxicology</i> , 0, , .	2.4	1
1296	Clinical features and management issues of NAFLD-related HCC: what we know so far. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 31-43.	1.4	4
1297	Efficacy and safety of radiofrequency ablation and surgery for hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e32470.	0.4	1
1298	Clinical value of serum α -fetoprotein (AFP) and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2023, 37, .	0.9	10
1299	Genetic and epigenetic analysis of hepatocellular adenomas with atypical morphological features. <i>Histopathology</i> , 2023, 82, 722-730.	1.6	1
1300	Prognostic value of des γ -carboxyprothrombin in patients with AFP-negative HCC treated with TACE. <i>Oncology Letters</i> , 2022, 25, .	0.8	0
1301	The Clinical Relevance and Immune Correlation of SLC10 Family Genes in Liver Cancer. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1415-1431.	1.8	5
1302	New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 437.	1.8	10
1303	Characterization of a lipid droplet and endoplasmic reticulum stress related gene risk signature to evaluate the clinical and biological value in hepatocellular carcinoma. <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	1
1304	Deciphering Tumour Microenvironment of Liver Cancer through Deconvolution of Bulk RNA-Seq Data with Single-Cell Atlas. <i>Cancers</i> , 2023, 15, 153.	1.7	2
1305	Apolipoprotein A-IV Has Bi-Functional Actions in Alcoholic Hepatitis by Regulating Hepatocyte Injury and Immune Cell Infiltration. <i>International Journal of Molecular Sciences</i> , 2023, 24, 670.	1.8	1
1306	Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 217-229.	4.5	8
1307	Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress. <i>Oncology Research</i> , 2022, 30, 201-210.	0.6	4
1308	Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 625.	1.7	7
1309	Bioactive substances inhibiting COX-2 and cancer cells isolated from the fibrous roots of <i>Alangium chinense</i> (Lour.) Harms. <i>RSC Advances</i> , 2023, 13, 3346-3363.	1.7	3
1310	Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-14.	1.9	1

#	ARTICLE	IF	CITATIONS
1311	In silico approach and immunohistochemical evaluation of Azadirachta indica bioactive compound as Hsp90 inhibitor and AIF inducer in hepatocellular carcinoma. AIP Conference Proceedings, 2023, , .	0.3	0
1312	Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities. , 2023, 40, .		0
1313	Lactobacillus for ribosome peptide editing cancer. Clinical and Translational Oncology, 0, , .	1.2	1
1314	Poor Prognostic Biomarker KIAA1522 Is Associated with Immune Infiltrates in Hepatocellular Carcinoma. Journal of Oncology, 2023, 2023, 1-15.	0.6	2
1315	Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma. Radiology, 2023, 307, .	3.6	21
1316	Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Frontiers in Immunology, 0, 14, .	2.2	1
1318	Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization. Frontiers in Oncology, 0, 13, .	1.3	0
1319	Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma. ELife, 0, 12, .	2.8	3
1320	Influence of key histological characteristics on 18F-fluorodeoxyglucose /18F-choline positron emission tomography positivity in hepatocellular carcinoma: A machine learning study. Frontiers in Medicine, 0, 10, .	1.2	0
1321	A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort. Frontiers in Endocrinology, 0, 14, .	1.5	2
1322	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective. Clinical and Molecular Hepatology, 2023, 29, 230-241.	4.5	8
1323	Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 854.	1.7	2
1324	Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib. Anticancer Research, 2023, 43, 911-918.	0.5	0
1325	Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma. Frontiers in Oncology, 0, 13, .	1.3	1
1326	Bispecific Antibodies in Targeted Cancer Immunotherapy. , 2023, , 1-46.		1
1327	Prognostic factors for long-term outcome in bifocal hepatocellular carcinoma after resection. European Radiology, 2023, 33, 3604-3616.	2.3	3
1328	eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 2055.	1.8	1
1329	ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation. Scientific Reports, 2023, 13, .	1.6	0

#	ARTICLE	IF	CITATIONS
1330	Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. <i>Asian Journal of Pharmaceutical Sciences</i> , 2023, 18, 100771.	4.3	6
1331	Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 593.	1.7	4
1332	The Effect of the Histone Chaperones HSPA8 and DEK on Tumor Immunity in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2653.	1.8	3
1333	Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	3
1334	Bodywide ecological interventions on cancer. <i>Nature Medicine</i> , 2023, 29, 59-74.	15.2	17
1335	Local tumor control of intermediate and advanced stage hepatocellular carcinoma after local ablative treatment with image-guided interstitial high-dose-rate brachytherapy: A subgroup analysis of 286 HCC nodules. <i>Brachytherapy</i> , 2023, , .	0.2	0
1336	Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1337	In Vivo, Ex Vivo, and In Vitro Model Systems for Liver Cancer Research. , 2023, , 353-373.		0
1338	Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1339	Biodegradation and Cytotoxic Effects of Biosurfactants. , 2023, , 95-116.		0
1340	Fructose Metabolism in Tumor Endothelial Cells Promotes Angiogenesis by Activating AMPK Signaling and Mitochondrial Respiration. <i>Cancer Research</i> , 2023, 83, 1249-1263.	0.4	2
1341	EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2023, 164, 1006-1008.e3.	0.6	5
1342	Is 18F-FDG/18F-Choline Dual-Tracer PET Behavior a Surrogate of Tumor Differentiation in Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	1
1343	Identification of Potential Hub Genes Related to Aflatoxin B1, Liver Fibrosis and Hepatocellular Carcinoma via Integrated Bioinformatics Analysis. <i>Biology</i> , 2023, 12, 205.	1.3	3
1344	Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
1345	HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like) Tj ETQq1,1 0.784314 rgBT	1.7	0
1346	Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA. <i>Cancers</i> , 2023, 15, 817.	1.7	4
1347	Ordered Labeling-Facilitated Electrochemical Assay of Alpha-Fetoprotein-L3 Ratio for Diagnosing Hepatocellular Carcinoma. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 6411-6419.	4.0	3

#	ARTICLE	IF	CITATIONS
1348	The combination of <sc>ALBI</sc> and <sc>AFP</sc> response: A small step forward in <sc>HCC</sc>. <i>Liver International</i> , 2023, 43, 271-273.	1.9	0
1349	New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells. <i>Pharmaceutics</i> , 2023, 15, 466.	2.0	7
1350	Detection of key mRNAs in liver tissue of hepatocellular carcinoma patients based on machine learning and bioinformatics analysis. <i>MethodsX</i> , 2023, 10, 102021.	0.7	2
1351	Complications of 90Y Radioembolization Treatment for Liver Tumors. <i>Digestive Disease Interventions</i> , 2023, 07, 138-144.	0.3	1
1352	The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 949.	1.0	9
1353	<sc>IFN̈́</sc>-mediated <sc>NK2R</sc> expression is involved in the induction of antitumor effector <sc>CD8</sc> T cells in vivo. <i>Cancer Science</i> , 0, , .	1.7	4
1354	Association between Foxo3 protein 43 overexpression and hepatocellular carcinoma pathogenesis and prognosis. <i>Cancer Medicine</i> , 2023, 12, 10062-10076.	1.3	2
1356	Pomegranate Peel Extract Sensitizes Hepatocellular Carcinoma Cells to Ionizing Radiation, Induces Apoptosis and Inhibits MAPK, JAK/STAT3, β -Catenin/NOTCH, and SOCS3 Signaling. <i>Integrative Cancer Therapies</i> , 2023, 22, 153473542211510.	0.8	3
1357	Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 293-319.	4.5	3
1358	Integrated analysis revealing the role of TET3-mediated MUC13 promoter hypomethylation in hepatocellular carcinogenesis. <i>Epigenomics</i> , 2022, 14, 1579-1591.	1.0	1
1359	A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). <i>Future Oncology</i> , 2022, 18, 4465-4471.	1.1	1
1360	Effects of Ultrasound-Guided Microwave Ablation Therapy on Mental State and Quality of Life in Patients with Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2023, 13, 3125-3130.	0.0	0
1361	Specificity Proteins (SP) and Kr̈́ppel-like Factors (KLF) in Liver Physiology and Pathology. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4682.	1.8	5
1362	Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma. <i>Molecules</i> , 2023, 28, 2211.	1.7	2
1363	Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 273-286.	0.8	0
1364	Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	2
1365	ZNF385A and ZNF346 Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3155.	1.8	3
1366	Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1957-1969.	2.0	4

#	ARTICLE	IF	CITATIONS
1367	Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. <i>Cells</i> , 2023, 12, 612.	1.8	3
1368	Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2345-2354.	1.2	2
1369	Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. <i>Acta Biomaterialia</i> , 2023, 162, 98-109.	4.1	5
1370	A nationwide propensity score analysis comparing ablation and resection for hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2023, 127, 1125-1134.	0.8	2
1371	Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1372	Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4885.	1.8	5
1373	UCLH3 promotes hepatocellular carcinoma cell migration by de-ubiquitinating and stabilizing Vimentin. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1374	Coordination polysaccharide nanomissiles with size/charge dual-transformability and immunomicroenvironment-reeducating activity potentiate PD-1 blockade in hepatocellular carcinoma. <i>Chemical Engineering Journal</i> , 2023, 460, 141815.	6.6	4
1375	HIF-1 α -activated TMEM237 promotes hepatocellular carcinoma progression via the NPHP1/Pyk2/ERK pathway. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	3
1376	Interactions between driver genes shape the signaling pathway landscape and direct hepatocellular carcinoma therapy. <i>Cancer Science</i> , 2023, 114, 2386-2399.	1.7	3
1377	Iridium(III) complexes inhibit the proliferation and migration of BEL-7402 cells through the PI3K/AKT/mTOR signaling pathway. <i>Journal of Inorganic Biochemistry</i> , 2023, 241, 112145.	1.5	5
1378	Autophagy orchestrates resistance in hepatocellular carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114487.	2.5	6
1379	Inhibition of autophagy in macrophage promotes IL-1 β -mediated hepatocellular carcinoma progression via inflammasome accumulation and self-recruitment. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114560.	2.5	3
1380	Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma. <i>Computers in Biology and Medicine</i> , 2023, 158, 106872.	3.9	2
1381	MALT1 paracaspase is overexpressed in hepatocellular carcinoma and promotes cancer cell survival and growth. <i>Life Sciences</i> , 2023, 323, 121690.	2.0	4
1382	An exosome-related lncRNA signature correlates with prognosis, immune microenvironment, and therapeutic responses in hepatocellular carcinoma. <i>Translational Oncology</i> , 2023, 31, 101651.	1.7	8
1383	Epithelial-mesenchymal transition-related gene prognostic index and phenotyping clusters for hepatocellular carcinoma patients. <i>Cancer Genetics</i> , 2023, 274-275, 41-50.	0.2	1
1384	A selective androgen receptor modulator, S4, displays robust anti-cancer activity on hepatocellular cancer cells by negatively regulating PI3K/AKT/mTOR signalling pathway. <i>Gene</i> , 2023, 869, 147390.	1.0	3

#	ARTICLE	IF	CITATIONS
1385	Metal-organic framework decorated with glycyrrhetic acid conjugated chitosan as a pH-responsive nanocarrier for targeted drug delivery. <i>International Journal of Biological Macromolecules</i> , 2023, 240, 124370.	3.6	14
1386	A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma. <i>Journal of Pharmacological Sciences</i> , 2023, 152, 69-75.	1.1	1
1387	COLEC10 Induces Endoplasmic Reticulum Stress by Occupying GRP78 and Inhibits Hepatocellular Carcinoma. <i>Laboratory Investigation</i> , 2023, 103, 100130.	1.7	3
1388	Plumbagin is a novel GPX4 protein degrader that induces apoptosis in hepatocellular carcinoma cells. <i>Free Radical Biology and Medicine</i> , 2023, 203, 1-10.	1.3	9
1389	Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma. <i>Current Opinion in Pharmacology</i> , 2023, 70, 102365.	1.7	2
1390	Cuproptosis and its application in different cancers: an overview. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 2683-2693.	1.4	2
1391	USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
1392	TRPM2 regulates cell cycle through the Ca ²⁺ -CaM-CaMKII signaling pathway to promote HCC. <i>Hepatology Communications</i> , 2023, 7, .	2.0	4
1393	Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches. <i>Pharmaceutics</i> , 2023, 15, 1249.	2.0	0
1394	LINC00511, a future star for the diagnosis and therapy of digestive system malignant tumors. <i>Pathology Research and Practice</i> , 2023, 244, 154382.	1.0	0
1399	Rational combination of <sc>SHP2</sc> and <sc>mTOR</sc> inhibition for the treatment of hepatocellular carcinoma. <i>Molecular Oncology</i> , 2023, 17, 964-980.	2.1	3
1400	A novel sesquiterpene lactone fraction from <i>Eupatorium chinense</i> L. suppresses hepatocellular carcinoma growth by triggering ferritinophagy and mitochondrial damage. <i>Phytomedicine</i> , 2023, 112, 154671.	2.3	6
1401	High-performance assaying phosphatidylinositol proteoglycan 3 based on a dual-mode biosensor coupling near-infrared photoelectrochemical with ratiometric electrochemical sensing. <i>Sensors and Actuators B: Chemical</i> , 2023, 381, 133419.	4.0	7
1402	High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis. <i>JHEP Reports</i> , 2023, 5, 100684.	2.6	3
1403	Targetoid Primary Liver Malignancy in Chronic Liver Disease: Prediction of Postoperative Survival Using Preoperative MRI Findings and Clinical Factors. <i>Korean Journal of Radiology</i> , 2023, 24, 190.	1.5	1
1404	Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma. <i>Journal of Advanced Research</i> , 2023, 54, 133-146.	4.4	3
1405	Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT. <i>Phytomedicine</i> , 2023, 112, 154687.	2.3	1
1406	Glycoproteomic Analysis of Urinary Extracellular Vesicles for Biomarkers of Hepatocellular Carcinoma. <i>Molecules</i> , 2023, 28, 1293.	1.7	7

#	ARTICLE	IF	CITATIONS
1408	Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	10
1409	Engineered Platforms for Maturing Pluripotent Stem Cell-Derived Liver Cells for Disease Modeling. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 1147-1160.	2.3	1
1410	Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation. <i>World Journal of Meta-analysis</i> , 0, 11, 47-54.	0.1	0
1411	Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 431-439.	0.8	0
1412	The Role of Branched-Chain Amino Acid Supplementation in Combination with Locoregional Treatments for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 926.	1.7	5
1413	The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2805.	1.8	6
1415	Comparable Overall Survival in Patients with Hepatocellular Carcinoma Diagnosed within and outside a Surveillance Programme: The Potential Impact of Liver Cirrhosis. <i>Cancers</i> , 2023, 15, 978.	1.7	1
1416	Hypoxia-associated circPRDM4 promotes immune escape via HIF-1 β regulation of PD-L1 in hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	12
1417	DNA Nanoclusters Combined with One-Shot Radiotherapy Augment Cancer Immunotherapy Efficiency. <i>Advanced Materials</i> , 2023, 35, .	11.1	6
1418	Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	3
1419	Microsomal Prostaglandin E Synthase-1 and -2: Emerging Targets in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3049.	1.8	2
1420	Association of primary tumor location with long-term oncological prognosis following hepatectomy for hepatocellular carcinoma:A multicenter propensity score matching analysis. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1234-1241.	0.5	1
1421	Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study. <i>Liver Cancer</i> , 2023, 12, 321-338.	4.2	9
1422	Down-regulation of ALDOB during metabolic reprogramming mediates malignant behavior in hepatocellular carcinoma and insensitivity to postoperative adjuvant transarterial chemoembolization. <i>Clinical Science</i> , 2023, 137, 303-316.	1.8	2
1423	Microfluidics-Enabled Serial Assembly of Lipid-siRNA-sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. <i>Advanced Materials</i> , 2023, 35, .	11.1	6
1424	Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. <i>Hepatology International</i> , 2023, 17, 709-719.	1.9	17
1425	An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3324.	1.8	1
1426	The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2023, 24, .	1.5	4

#	ARTICLE	IF	CITATIONS
1427	Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	44
1428	The immune-metabolic crosstalk between CD3 ⁺ C1q ⁺ TAM and CD8 ⁺ T cells associated with relapse-free survival in HCC. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1430	A prospective diagnostic and prognostic biomarker for hepatocellular carcinoma that functions in glucose metabolism regulation: Solute carrier family 37 member 3. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166661.	1.8	1
1431	Social determinants of health impact mortality from HCC and cholangiocarcinoma: a population-based cohort study. <i>Hepatology Communications</i> , 2023, 7, e0058-e0058.	2.0	2
1432	Non-alcoholic fatty liver disease-related hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2023, 23, 127-142.	0.3	5
1433	NLRP3 inflammasome activation By 17 β -estradiol is a potential therapeutic target in hepatocellular carcinoma treatment. , 2023, 40, .		2
1434	The prognostic value of the GPAT/AGPAT gene family in hepatocellular carcinoma and its role in the tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1435	Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. <i>Digestive and Liver Disease</i> , 2023, 55, 907-917.	0.4	5
1436	An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	3
1437	The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancerâ€”Challenges and opportunities. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	4
1438	Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B. <i>Medicine (United States)</i> , 2023, 102, e32894.	0.4	1
1439	<scp>IOP</scp> Injection, A Novel Superparamagnetic Iron Oxide Particle <scp>MRI</scp> Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase <scp>II</scp> Clinical Trial. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 1177-1188.	1.9	4
1440	Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
1441	Ubiquitinâ€™conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review). <i>Oncology Reports</i> , 2023, 49, .	1.2	0
1442	Utility of comet assay of DNA damage in the detection of malignant transformation of chronic liver cirrhosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 145-151.	0.6	0
1443	Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	7
1444	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 593-604.	4.5	6
1445	Glycopolymers Mediate Suicide Gene Therapy in ASGPR-Expressing Hepatocellular Carcinoma Cells in Tandem with Docetaxel. <i>Biomacromolecules</i> , 2023, 24, 1274-1286.	2.6	4

#	ARTICLE	IF	CITATIONS
1446	Metabolism-related signatures is correlated with poor prognosis and immune infiltration in hepatocellular carcinoma via multi-omics analysis and basic experiments. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1447	Circulating DNA methylation profile improves the accuracy of serum biomarkers for the detection of nonmetastatic hepatocellular carcinoma. <i>Future Oncology</i> , 2022, 18, 4399-4413.	1.1	8
1448	VICT2 Trait: Prognostic Alternative to Peritumoral Hepatobiliary Phase Hypointensity in HCC. <i>Radiology</i> , 2023, 307, .	3.6	10
1449	Effectiveness and safety of lenvatinib plus anti- PD-1 antibodies in patients with hepatocellular carcinoma: A <i>real-world</i> cohort study. <i>Cancer Medicine</i> , 2023, 12, 9202-9212.	1.3	3
1450	Combinatorial treatment with <i>Silybum marianum</i> essential oil enhances the therapeutic efficacy of a 5-fluorouracil base therapy for hepatocellular carcinoma. <i>Phytotherapy Research</i> , 2023, 37, 1968-1985.	2.8	1
1451	Function of TRPC1 in modulating hepatocellular carcinoma progression. , 2023, 40, .		2
1452	Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy. <i>Drug Design, Development and Therapy</i> , 0, Volume 17, 507-518.	2.0	1
1453	A 3D Tumor-Mimicking In Vitro Drug Release Model of Locoregional Chemoembolization Using Deep Learning-Based Quantitative Analyses. <i>Advanced Science</i> , 2023, 10, .	5.6	2
1454	Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1455	The effects of low-dose sorafenib on epithelial-mesenchymal transition and multidrug resistance markers in HepG2 cell line. <i>The European Research Journal</i> , 0, , 1-8.	0.1	0
1456	Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma. <i>European Journal of Immunology</i> , 0, , 2250054.	1.6	2
1457	An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. <i>Biomedicines</i> , 2023, 11, 586.	1.4	2
1459	Mandibular Metastasis as the First Manifestation of Hepatocellular Carcinoma: A Case Report. <i>Case Reports in Oncology</i> , 0, , 94-101.	0.3	0
1460	Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2023, 30, S81-S91.	1.3	7
1461	Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2023, 2023, 1-22.	0.6	0
1462	Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview. <i>Current Oncology</i> , 2023, 30, 2493-2500.	0.9	7
1463	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. <i>Cancers</i> , 2023, 15, 1324.	1.7	1
1464	Collagen matrix scaffolds: Future perspectives for the management of chronic liver diseases. <i>World Journal of Clinical Cases</i> , 0, 11, 1224-1235.	0.3	0

#	ARTICLE	IF	CITATIONS
1465	Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C. <i>BMC Cancer</i> , 2023, 23, .	1.1	6
1466	Ferroptosis-Related Gene SLC1A5 Is a Novel Prognostic Biomarker and Correlates with Immune Microenvironment in HBV-Related HCC. <i>Journal of Clinical Medicine</i> , 2023, 12, 1715.	1.0	2
1467	Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4286.	1.8	11
1468	Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study. <i>GastroHep</i> , 2023, 2023, 1-12.	0.3	1
1469	Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1470	Editorial for "IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial". <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	1.9	0
1471	CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. <i>Current Oncology</i> , 2023, 30, 2653-2672.	0.9	2
1472	<i>Neolamarckia cadamba</i> (Roxb.) Bosser (Rubiaceae) extracts: promising prospects for anticancer and antibacterial potential through in vitro and in silico studies. , 2023, 40, .		3
1473	Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1474	TBS-Based Preoperative Score to Predict Non-transplantable Recurrence and Identify Candidates for Upfront Resection Versus Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2023, 30, 3363-3373.	0.7	8
1475	An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma. <i>Heliyon</i> , 2023, 9, e13989.	1.4	5
1476	Polyunsaturated Fatty Acid-Bound β -Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism. <i>Cancer Research</i> , 2023, 83, 1543-1557.	0.4	6
1477	Impact of dietary carbohydrate restriction on the pathobiology of Hepatocellular Carcinoma: The gut-liver axis and beyond. <i>Seminars in Immunology</i> , 2023, 66, 101736.	2.7	2
1478	Autophagy-Targeted Calcium Phosphate Nanoparticles Enable Transarterial Chemoembolization for Enhanced Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 11431-11443.	4.0	7
1479	PEGylated Liposomes Loaded with Carbamate Inhibitor ANP0903 Trigger Apoptosis by Enhancing ER Stress in HepG2 Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4552.	1.8	2
1480	The potential value of plasma Circ-ITCH in hepatocellular carcinoma patients with current hepatitis C virus infection. <i>Gastroenterology & Hepatology (English Edition)</i> , 2023, 46, 17-27.	0.0	0
1481	HIV: hepatic manifestations of HIV and antiretroviral therapy. , 2023, , 525-555.		0
1483	Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 357-367.	1.8	2

#	ARTICLE	IF	CITATIONS
1484	Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4855.	1.8	4
1486	The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors. <i>Seminars in Hematology</i> , 2023, 60, 42-51.	1.8	2
1487	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5002.	1.8	6
1488	Physics-based tissue simulator to model multicellular systems: A study of liver regeneration and hepatocellular carcinoma recurrence. <i>PLoS Computational Biology</i> , 2023, 19, e1010920.	1.5	0
1489	SPRED2: A Novel Regulator of Epithelial-Mesenchymal Transition and Stemness in Hepatocellular Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4996.	1.8	4
1490	Key genes associated with non-alcoholic fatty liver disease and hepatocellular carcinoma with metabolic risk factors. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
1491	TUBB2B facilitates progression of hepatocellular carcinoma by regulating cholesterol metabolism through targeting HNF4A/CYP27A1. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1
1492	Liver transplantation in metastatic colorectal cancer: are we ready for it?. <i>British Journal of Cancer</i> , 2023, 128, 1797-1806.	2.9	5
1493	Identification of fatty acid metabolism-related clusters and immune infiltration features in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	0
1495	Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1496	Differentially expressed discriminative genes and significant meta-hub genes based key genes identification for hepatocellular carcinoma using statistical machine learning. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
1497	A Bibliometric Analysis of the Role of 3D Technology in Liver Cancer Resection. <i>World Journal of Surgery</i> , 2023, 47, 1548-1561.	0.8	1
1498	Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	1
1499	Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. <i>Journal of Hepatology</i> , 2023, 79, 538-551.	1.8	27
1500	A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. <i>Gastroenterology</i> , 2023, 164, 1279-1292.	0.6	8
1501	Risk prediction of hepatobiliary and pancreatic cancers in elderly Chinese: The Dongfengâ€¦Tongji cohort. <i>Journal of Evidence-Based Medicine</i> , 2023, 16, 39-49.	0.7	0
1502	The exposome and liver disease - how environmental factors affect liver health. <i>Journal of Hepatology</i> , 2023, 79, 492-505.	1.8	14
1503	Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 16, 133-159.	2.3	22

#	ARTICLE	IF	CITATIONS
1504	Association between telomere length and hepatocellular carcinoma risk: A Mendelian randomization study. <i>Cancer Medicine</i> , 2023, 12, 9937-9944.	1.3	3
1506	Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1313-1325.	1.9	14
1508	Spontaneously Ruptured Hepatocellular Carcinoma: Computed Tomography-Based Assessment. <i>Diagnostics</i> , 2023, 13, 1021.	1.3	2
1509	Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. <i>Vaccines</i> , 2023, 11, 614.	2.1	4
1510	Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. <i>Liver Cancer International</i> , 0, , .	0.2	0
1511	MYC determines lineage commitment in KRAS-driven primary liver cancer development. <i>Journal of Hepatology</i> , 2023, 79, 141-149.	1.8	5
1512	Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1514	Screening of liver cancer with abbreviated MRI. <i>Hepatology</i> , 2023, 78, 670-686.	3.6	5
1515	USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	6
1516	FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. <i>Journal of Hepatology</i> , 2023, 79, 109-125.	1.8	20
1517	Cytotoxic effect of bionanocatalysts evaluated by diffuse reflectance spectroscopy in an in vivo model of hepatocellular carcinoma. <i>Results in Chemistry</i> , 2023, 5, 100894.	0.9	2
1518	Immunotherapy for advanced or recurrent hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 405-424.	0.8	0
1519	Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2023, 152, 2615-2628.	2.3	3
1520	Advances of High-Intensity Focused Ultrasound Ablation in the Treatment of Primary Liver Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 3234-3240.	0.0	0
1521	In Vivo and in Vitro Biocompatibility Studies of Pt Based Nanoparticles: a New Agent for Chemoradiation Therapy. <i>Journal of Cluster Science</i> , 2023, 34, 2653-2663.	1.7	1
1522	ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2023, 36, 299-311.	0.8	0
1523	Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1524	Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0

#	ARTICLE	IF	CITATIONS
1525	The expression, immune infiltration, prognosis, and experimental validation of OSBPL family genes in liver cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
1526	Macrophage-Derived MMP-9 and MMP-2 are Closely Related to the Rupture of the Fibrous Capsule of Hepatocellular Carcinoma Leading to Tumor Invasion. <i>Biological Procedures Online</i> , 2023, 25, .	1.4	6
1527	Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	6
1528	The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1529	A novel risk score model based on pyroptosis-related genes for predicting survival and immunogenic landscape in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	1
1530	AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway. <i>Molecular Carcinogenesis</i> , 2023, 62, 833-844.	1.3	7
1531	Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?. <i>Targeted Oncology</i> , 2023, 18, 221-233.	1.7	9
1532	A key driver to promote HCC: Cellular crosstalk in tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
1533	Significance of nucleogenesis, ribogenesis, and nucleolar proteome in the pathogenesis and recurrence of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 363-378.	1.4	0
1534	SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma. <i>Free Radical Biology and Medicine</i> , 2023, 201, 41-54.	1.3	4
1535	Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	3
1536	Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. <i>Cancers</i> , 2023, 15, 1798.	1.7	9
1537	Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice. <i>Nutrients</i> , 2023, 15, 1447.	1.7	2
1538	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 487-503.	8.2	55
1539	Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
1540	Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective studies. <i>International Immunopharmacology</i> , 2023, 118, 110019.	1.7	15
1541	A novel nomogram predicting the early recurrence of hepatocellular carcinoma patients after R0 resection. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1542	Integrated Analysis of N1-Methyladenosine Methylation Regulators-Related lncRNAs in Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 1800.	1.7	1

#	ARTICLE	IF	CITATIONS
1543	Smart anti-vascular nanoagent induces positive feedback loop for self-augmented tumor accumulation. <i>Journal of Controlled Release</i> , 2023, 356, 595-609.	4.8	2
1544	Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 395-403.	1.4	1
1545	Overexpression of YEATS2 Remodels the Extracellular Matrix to Promote Hepatocellular Carcinoma Progression via the PI3K/AKT Pathway. <i>Cancers</i> , 2023, 15, 1850.	1.7	6
1546	Utilizing Estra-1,3,5,16-Tetraene Scaffold: Design and Synthesis of Nitric Oxide Donors as Chemotherapeutic Resistance Combating Agents in Liver Cancer. <i>Molecules</i> , 2023, 28, 2754.	1.7	0
1547	Above-Standard Survival of Hepatocellular Carcinoma as the Final Outcome of Comprehensive Hepatology Care Programs in a Remote HCV-Endemic Area. <i>Viruses</i> , 2023, 15, 786.	1.5	0
1548	Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy. <i>Cancers</i> , 2023, 15, 1834.	1.7	2
1549	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
1550	PFKFB4 Is a Metabolic Driver of HCC Progression and Chemoresistance Through ROS Mitigation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 1527-1529.	2.3	2
1551	Application of PD-1 and PD-L1 inhibitors in immunotherapy of cancer. , 0, 36, 420-426.		0
1552	Monoclonal Antibodies in Cancer Immunotherapy. , 0, 36, 902-908.		0
1553	Circular RNA hsa_circ_0005218 promotes the early recurrence of hepatocellular carcinoma by targeting the miR-31-5p/CDK1 pathway. <i>Heliyon</i> , 2023, 9, e14816.	1.4	2
1554	Alcoholic Liver Disease-Related Hepatocellular Carcinoma: Characteristics and Comparison to General Slovak Hepatocellular Cancer Population. <i>Current Oncology</i> , 2023, 30, 3557-3570.	0.9	1
1555	Cause analysis of post-mortem diagnosis of hepatocellular carcinoma. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2023, 12, 42.	0.3	1
1556	The Comprehensive Effects of <i>Carassius auratus</i> Complex Formula against Lipid Accumulation, Hepatocarcinogenesis, and COVID-19 Pathogenesis via Stabilized G-Quadruplex and Reduced Cell Senescence. <i>Advanced Biology</i> , 0, , 2200310.	1.4	0
1558	The Microbiome and Liver Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2023, 29, 57-60.	1.0	2
1559	Progress in the Study of Hepatocellular Carcinoma Microenvironment and Its Clinical Significance. <i>Advances in Clinical Medicine</i> , 2023, 13, 4415-4420.	0.0	0
1560	DHMMF, a natural flavonoid from <i>Resina Draconis</i> , inhibits hepatocellular carcinoma progression via inducing apoptosis and G2/M phase arrest mediated by DNA damage-driven upregulation of p21. <i>Biochemical Pharmacology</i> , 2023, 211, 115518.	2.0	3
1561	Ferroptosis in gastrointestinal cancer: from mechanisms to implications. <i>Cancer Letters</i> , 2023, 561, 216147.	3.2	13

#	ARTICLE	IF	CITATIONS
1562	A hemoglobin-based oxygen-carrying biomimetic nanosystem for enhanced chemo-phototherapy and hypoxia alleviation of hepatocellular carcinoma. <i>Journal of Industrial and Engineering Chemistry</i> , 2023, 123, 330-341.	2.9	1
1563	Mitochondrial ROS driven by NOX4 upregulation promotes hepatocellular carcinoma cell survival after incomplete radiofrequency ablation by inducing of mitophagy via Nrf2/PINK1. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	8
1564	The predictive value of <sc>PD</sc> expression in patients with advanced hepatocellular carcinoma treated with <sc>PD</sc> inhibitors: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2023, 12, 9282-9292.	1.3	8
1565	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. <i>Liver Cancer International</i> , 2023, 4, 58-72.	0.2	0
1566	Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. <i>Journal of Gastroenterology</i> , 2023, 58, 413-424.	2.3	10
1567	iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	6
1568	ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma. <i>Cancer Cell International</i> , 2023, 23, .	1.8	0
1569	Management of hepatocellular carcinoma from diagnosis in routine clinical practice. <i>Hepatic Oncology</i> , 2022, 9, .	4.2	0
1570	Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1571	Patient Selection and Outcomes of Laparoscopic Microwave Ablation of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 1965.	1.7	1
1572	Plant-made vaccines against viral diseases in humans and farm animals. <i>Frontiers in Plant Science</i> , 0, 14, .	1.7	6
1573	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1574	Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7565-7577.	1.2	5
1575	Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations. <i>Cancers</i> , 2023, 15, 2001.	1.7	5
1576	Near-infrared fluorescence imaging of hepatocellular carcinoma cells regulated by β -catenin signaling pathway. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1577	Machine Learning-Based Radiomic Features on Pre-Ablation MRI as Predictors of Pathologic Response in Patients with Hepatocellular Carcinoma Who Underwent Hepatic Transplant. <i>Cancers</i> , 2023, 15, 2058.	1.7	2
1578	NHC-gold(I)-alkyne complexes induced hepatocellular carcinoma cell death through bioorthogonal activation by palladium complex in living system. <i>Chinese Chemical Letters</i> , 2023, 34, 108413.	4.8	1
1579	Myokines: Crosstalk and Consequences on Liver Physiopathology. <i>Nutrients</i> , 2023, 15, 1729.	1.7	4

#	ARTICLE	IF	CITATIONS
1580	Malignant tumours of the liver. <i>Surgery</i> , 2023, , .	0.1	0
1581	High Expression of Heterogeneous Nuclear Ribonucleoprotein A1 Facilitates Hepatocellular Carcinoma Growth. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 517-530.	1.8	2
1582	Three-dimensional and single-cell sequencing of liver cancer reveals comprehensive host-virus interactions in HBV infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1583	Identification and Experimental Validation of the Prognostic Significance and Immunological Correlation of Glycosylation-Related Signature and ST6GALNAC4 in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 531-551.	1.8	1
1584	Prognostic value of systemic immune-inflammation index/ albumin for transcatheter arterial chemoembolization treatment. <i>Heliyon</i> , 2023, 9, e15156.	1.4	1
1585	Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1586	Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment. <i>JGH Open</i> , 2023, 7, 249-260.	0.7	0
1587	Ferroptosis in hepatocellular carcinoma: from bench to bedside. <i>Hepatology</i> , 0, Publish Ahead of Print, .	3.6	14
1588	The future of hepatology. <i>Hepatology</i> , 2023, 78, 637-648.	3.6	1
1589	Effects of 3â€HAA on HCC by Regulating the Heterogeneous Macrophagesâ€”A scRNAâ€Seq Analysis. <i>Advanced Science</i> , 0, , .	5.6	1
1590	The Synergistic Effects of Multidrugâ€Loaded Nanocarriers Improve Tumor Microenvironment Responsive Chemoâ€Sonodynamic Therapy of Hepatocellular Carcinoma. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	2
1591	Expression of the Non-classical HLA-E, -F, -G Molecules in the Tumour Microenvironment. <i>Forum of Clinical Oncology</i> , 2023, .	0.1	0
1592	Lipidomic study and diagnosis of hepatocellular carcinoma tumor with rapid evaporative ionization mass spectrometry. <i>Electrophoresis</i> , 0, , .	1.3	0
1593	Dictionary learning LASSO for feature selection with application to hepatocellular carcinoma grading using contrast enhanced magnetic resonance imaging. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1594	iMSEA: A Novel Metabolite Set Enrichment Analysis Strategy to Decipher Drug Interactions. <i>Analytical Chemistry</i> , 2023, 95, 6203-6211.	3.2	6
1595	miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFÎ²R2. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	1
1596	PPDPF suppresses the development of hepatocellular carcinoma through TRIM21-mediated ubiquitination of RIPK1. <i>Cell Reports</i> , 2023, 42, 112340.	2.9	3
1597	Computational analysis of natural compounds targeted for NICD of notch pathway in hepatocellular carcinoma. <i>Materials Today: Proceedings</i> , 2023, , .	0.9	0

#	ARTICLE	IF	CITATIONS
1598	PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	2
1599	SIAH1/CTR9 axis promotes the epithelial-mesenchymal transition of hepatocellular carcinoma. <i>Carcinogenesis</i> , 0, , .	1.3	1
1600	Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	1
1601	Coffee, Green Tea Intake, and the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Observational Studies. <i>Nutrition and Cancer</i> , 2023, 75, 1295-1308.	0.9	6
1602	Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study. <i>International Journal of Surgery</i> , 0, Publish Ahead of Print, .	1.1	2
1603	Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	3
1604	HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia. <i>Journal of Hepatology</i> , 2023, 79, 378-393.	1.8	8
1605	Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes. <i>Cell Stem Cell</i> , 2023, 30, 617-631.e8.	5.2	10
1606	Cellular senescence-related gene signature as a valuable predictor of prognosis in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	1
1607	Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. <i>Biomedicines</i> , 2023, 11, 1166.	1.4	6
1608	Normalization of Tumor Vessels by Lenvatinib-Based Metallo-Nanodrugs Alleviates Hypoxia and Enhances Calreticulin-Mediated Immune Responses in Orthotopic HCC and Organoids. <i>Small</i> , 2023, 19, .	5.2	5
1609	Single-nucleus RNA sequencing of pre-malignant liver reveals disease-associated hepatocyte state with HCC prognostic potential. <i>Cell Genomics</i> , 2023, 3, 100301.	3.0	4
1610	Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation. <i>Engineering</i> , 2023, 29, 59-72.	3.2	8
1611	Role of ferroptosis and its non-coding RNA regulation in hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1612	The pre- and postoperative nomograms to predict the textbook outcomes of patients who underwent hepatectomy for hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1613	Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. <i>Journal of Oncology</i> , 2023, 2023, 1-8.	0.6	3
1614	Role of β -Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 2311.	1.7	6
1615	A View on Drug Development for Cancer Prevention. <i>Cancer Discovery</i> , 2023, 13, 1058-1083.	7.7	2

#	ARTICLE	IF	CITATIONS
1616	A systems biology-based approach to screen key splicing factors in hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2023, 62, 1107-1118.	1.3	1
1617	Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers. <i>Diagnostics</i> , 2023, 13, 1442.	1.3	2
1618	Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 737-750.	1.9	3
1619	CRISPR/Cas9 genetic screens in hepatocellular carcinoma gene discovery. <i>Current Research in Biotechnology</i> , 2023, 5, 100127.	1.9	1
1622	RNF8 Depletion Attenuates Hepatocellular Carcinoma Progression by Inhibiting Epithelial Mesenchymal Transition and Enhancing Drug Sensitivity. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, , .	0.9	1
1623	Predictive Value of Peripheral Blood Markers in Hepatocellular Carcinoma Patients Treated with Anti-PD-1 in Combination with Targeted Therapy. <i>Journal of Cancer Therapy</i> , 2023, 14, 127-138.	0.1	0
1624	Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7463.	1.8	9
1625	Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen. , 2023, 11, e006334.		0
1627	The Role of Oxidative Stress in the Development and Therapeutic Intervention of Hepatocellular Carcinoma. <i>Current Cancer Drug Targets</i> , 2023, 23, 792-804.	0.8	2
1628	A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 659-671.	1.8	4
1629	Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma. <i>BMC Medical Genomics</i> , 2023, 16, .	0.7	1
1630	Epigenetic memory of environmental exposures as a mediator of liver disease. <i>Hepatology</i> , 0, Publish Ahead of Print, .	3.6	1
1631	Six-Transmembrane Epithelial Antigen of Prostate 4: An Indicator of Prognosis and Tumor Immunity in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 643-658.	1.8	1
1632	Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2183-2192.	2.4	2
1633	An MRI-based Prognostic Stratification System for Medical Decision-Making of Multinodular Hepatocellular Carcinoma Patients Beyond the Milan Criteria. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	1.9	0
1634	PAIP1 regulates expression of immune and inflammatory response associated genes at transcript level in liver cancer cell. <i>PeerJ</i> , 0, 11, e15070.	0.9	1
1635	The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma. <i>Advanced Science</i> , 2023, 10, .	5.6	5
1636	Procedural technique development. , 2023, , 81-86.		0

#	ARTICLE	IF	CITATIONS
1637	Loss of the Novel Mitochondrial Membrane Protein FAM210B Is Associated with Hepatocellular Carcinoma. <i>Biomedicines</i> , 2023, 11, 1232.	1.4	0
1638	Comprehensive Analysis of NABP2 as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma. <i>Journal of Inflammation Research</i> , 0, Volume 16, 1783-1804.	1.6	0
1639	Runt-related transcription factors in human carcinogenesis: a friend or foe?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 9409-9423.	1.2	0
1640	FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	3
1641	Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1 α to inhibit apoptosis. <i>Biomedicine and Pharmacotherapy</i> , 2023, 163, 114750.	2.5	2
1659	Proteomic Research on the Therapeutic Properties of Medicinal Mushrooms. , 2023, , 309-344.		0
1698	Exosomes and circular RNAs: promising partners in hepatocellular carcinoma from bench to bedside. <i>Discover Oncology</i> , 2023, 14, .	0.8	1
1713	The interplay between N6-methyladenosine and precancerous liver disease: molecular functions and mechanisms. <i>Discover Oncology</i> , 2023, 14, .	0.8	1
1717	On the Stiffness Modelling of the ProHep-LCT Robotic Needle Insertion Instrument. <i>Mechanisms and Machine Science</i> , 2023, , 245-252.	0.3	1
1744	Deuterium in drug discovery: progress, opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 562-584.	21.5	51
1762	Cancers digestifs. , 2023, , 199-205.		0
1830	Tumor infiltrating lymphocytes and radiological picture of the tumor. , 2023, 40, .		1
1851	The role of myeloid-derived suppressor cells in liver cancer. <i>Discover Oncology</i> , 2023, 14, .	0.8	2
1868	Editorial: Identification and characterization of molecular targets in hepatocellular carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	1
1885	The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Obesity Reports</i> , 2023, 12, 191-206.	3.5	13
1907	US-guided ablation of tumors “ where is it used and how did we get there. , 2023, 1, .		0
1914	Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion. <i>European Radiology</i> , 2023, 33, 9167-9181.	2.3	1
1962	Insights into Irirogenin: A Natural Isoflavonoid. , 2023, , 1-28.		0

#	ARTICLE	IF	CITATIONS
1970	Hepatocellular carcinoma surveillance "utilization, barriers and the impact of changing aetiology. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 797-809.	8.2	12
1983	Friend or foe? The elusive role of hepatic stellate cells in liver cancer. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 647-661.	8.2	11
2003	Circ_0067934: a circular RNA with roles in human cancer. Human Cell, 2023, 36, 1865-1876.	1.2	1
2005	Zwitterionic mesoporous engineering aids peptide-dependent pattern profiling for identification of different liver diseases. Chemical Communications, 0, , .	2.2	1
2057	Biomarkers for immunotherapy of hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 780-798.	12.5	5
2096	Phospholipase inhibitors as cancer therapy in hepatocellular carcinoma. , 2023, , 173-179.		0
2115	Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology, 2023, 20, 864-884.	12.5	14
2157	Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary"pancreatic cancers. Journal of Gastroenterology, 2023, 58, 1081-1093.	2.3	1
2184	Electrochemical Biosensors for Tumor Biomarkers Detection. , 2023, , 197-216.		0
2205	Drugs for TACE of HCC. , 2023, , 89-94.		0
2226	Automatic recognition of tumor region in multiphoton images of hepatocellular carcinoma using a convolutional neural network. , 2023, , .		0
2245	Molecular pathology of hepatocellular carcinoma. , 2024, , 561-568.		0
2252	The Genetics of Alcohol-Related Liver Disease. , 2023, , 975-996.		0
2265	Decoding the role of aberrant RNA alternative splicing in hepatocellular carcinoma: a comprehensive review. Journal of Cancer Research and Clinical Oncology, 2023, 149, 17691-17708.	1.2	0
2270	Fifteen-year survival of a hepatocellular carcinoma extending into the right atrium treated by surgical resection with the heart-first approach under cardiopulmonary bypass: a case report and review of the literature. Clinical Journal of Gastroenterology, 0, , .	0.4	0
2287	Can iron chelators ameliorate viral infections?. BioMetals, 0, , .	1.8	0
2290	Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	0
2320	The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 3953-3969.	2.0	0

#	ARTICLE	IF	CITATIONS
2337	Radiomic analysis of pretreatment imaging in hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE): treatment response and survival. <i>Endoscopy</i> , 2023, , .	1.0	0
2424	Application of the Human Amniotic Membrane as an Adjuvant Therapy for the Treatment of Hepatocellular Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2023, , .	0.8	0
2445	Computer-Aided Diagnosis for Liver Tumor Feature Extraction. , 2023, , .		0
2493	RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2024, 21, 267-281.	8.2	0
2536	Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype. <i>Discover Oncology</i> , 2024, 15, .	0.8	0
2538	The dual function of cGAS-STING signaling axis in liver diseases. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	0
2561	Two-Dimensional (2D) Based Hybrid Polymeric Nanoparticles as Novel Potential Therapeutics in the Treatment of Hepatocellular Carcinoma. <i>Engineering Materials</i> , 2024, , 329-349.	0.3	0
2592	Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts. <i>Current Hepatology Reports</i> , 0, , .	0.4	0
2593	Hydrodynamic Transfection of Hepatocytes for the Study of Hepatocellular Carcinogenesis. <i>Methods in Molecular Biology</i> , 2024, , 77-85.	0.4	0
2598	Targeted Analysis of Glycerophospholipids and Mono-, Di-, or Tri-Acylglycerides in Liver Cancer. <i>Methods in Molecular Biology</i> , 2024, , 189-198.	0.4	0
2599	Diethylnitrosamine-Induced Liver Tumorigenesis in Mice Under High-Fat High-Sucrose Diet: Stepwise High-Resolution Ultrasound Imaging and Histopathological Correlations. <i>Methods in Molecular Biology</i> , 2024, , 27-55.	0.4	0
2680	An Overview of the Unfolded Protein Response (UPR) and Autophagy Pathways in Human Viral Oncogenesis. <i>International Review of Cell and Molecular Biology</i> , 2024, , .	1.6	0
2755	The Role of MR-Guided Radiation Therapy in the Management of Liver Malignancies. , 2024, , 257-271.		0